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Background:  Fatigue  is  common  after  traumatic  brain  injury  (TBI).  Its  risk  factors,  natural  history  and
consequences  are  uncertain.  Best-evidence  synthesis  was  used  to address  the gaps.
Methods:  Five  databases  were  searched  for relevant  peer-reviewed  studies.  Of the  33  articles  appraised,
22  longitudinal  studies  were  selected.  Results  were  reported  separately  based  on  their  timing  of  baseline
assessment.
Results:  All  studies  document  changes  in  fatigue  frequency  and  severity  with  time,  irrespective  of setting
or  TBI  severity.  There  is  limited  evidence  for certain  clinical  and  psychosocial  variables  as predictors  of
fatigue  severity  at  follow-up.  Early  fatigue  severity  predicted  persistent  post-concussive  symptoms  and
Glasgow  outcome  score  at follow-up.ehabilitation
ystematic review
Conclusions:  Fatigue  is  present  before  and  immediately  following  injury,  and  can  persist  long term.  The
variation  in  ﬁndings  supports  the idea of  fatigue  in  TBI as  a nonhomogeneous  entity,  with  different  factors
inﬂuencing  the course  of  new  onset  or chronic  fatigue.  To decrease  the  heterogeneity,  we emphasize  the
need  for agreement  on  a core set  of  relevant  fatigue  predictors,  deﬁnitions  and  outcome  criteria.
PROSPERO  registry  number:  CRD42013004262.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations: APOE-4, apolipoprotein-4; BDI, Beck depression inventory; BFS, Barosso fatigue scale; CHART, Craig handicap assessment and reporting technique;
NS,  central nervous system; DRS, disability rating scale; FSS, fatigue severity scale; GCS, Glasgow coma scale; GOSE, Glasgow outcome scale-extended; GFI, global fatigue
nventory; HADS, hospital anxiety and depression scale; MFIS, modiﬁed fatigue impact scale; MFI, multidimentional fatigue inventory; mTBI, mild traumatic brain injury;
RISMA, preferred reporting items for systematic reviews and meta-analyses; PCSC, post-concussion syndrome checklist; POMS, proﬁle of moods scale; RCT, randomized
ontrolled trial; RPQ, Rivermead post-concussive questionnaire; SIGN, Scottish intercollegiate guidelines network; SF-36, 36-item short form health survey (from medical
utcomes study); TBI, traumatic brain injury; VAS, visual analog scale.
∗ Corresponding author at: Toronto Rehabilitation Institute, 550 University Avenue, Rm 11207, Toronto, Ontario M5G  2A2, Canada. Tel.: +1 416 597 3422x7848;
ax:  +416 946 8570.
E-mail addresses: tatyana.mollayeva@utoronto.ca (T. Mollayeva), tetyana.kendzerska@mail.utoronto.ca (T. Kendzerska), shirin.mollayeva@utoronto.ca (S. Mollayeva),
olinshapiro@rogers.com (C.M. Shapiro), angela.colantonio@utoronto.ca (A. Colantonio), dcassidy@health.sdu.dk (J.D. Cassidy).
1 Tel.: +1 416 669 6759; fax: +1 416 946 8570.
2 Tel.: +1 416 978 1098; fax: +1 416 946 8570.
3 Tel.: +1 416 603 5800x5160; fax: +1 416 603 5292.
4 Address: Saunderson Family Chair in Acquired Brain Injury Research, Toronto Rehabili
5G  1V7, Canada. Tel.: +1 416 978 1098; fax: +1 416 946 8570.
5 Tel.: +45 6550 3471; fax: +45 2328 5051.
ttp://dx.doi.org/10.1016/j.neubiorev.2014.10.024
149-7634/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article untation Institute, University of Toronto, 160-500 University Avenue, Toronto, Ontario
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
C1
f
n
t
a
b
d
l
M
c
2
t
a
t
w
E
7
(
a
s
1T. Mollayeva et al. / Neuroscience and Biobehavioral Reviews 47 (2014) 684–716 685
ontents
1. Background  .  . . . . . . .  . . . .  . . .  . . . .  . . .  .  .  . .  .  . . .  . . . . . . . . . . . .  . . . .  . . . . . .  .  . . .  . . . .  .  . .  . . . . .  . .  . . .  . . . . . . . . .  . . . . . . .  .  .  . . .  . .  .  . . . . . .  .  . . . .  . .  .  . . . .  . . . . .  . . .  .  .  .  .  . . . . . .  . . .  . . 685
2.  Methods/design  .  .  .  . . .  .  . . . . . . .  . . .  .  . . .  .  . . .  .  . . .  . . . . . . . . . . . . . . .  . . .  . . . . . .  .  .  . . .  . . . . . . . . .  . . .  . . . .  .  . . . . .  . . .  . . . . . .  .  .  . .  . . . . .  . . .  . . . .  .  .  . . .  . .  .  . . . .  .  .  . . . . .  . . .  . .  . . . .  686
2.1.  Data  sources  and  searches  . . . .  . . .  .  . . .  .  . . . .  .  . .  .  . . .  . . .  .  . . . . . .  .  .  .  . .  . . .  . .  . .  . . .  . . . . . . .  .  . .  . . . . .  .  . .  . . . . .  . . .  . . .  . .  . .  . . .  .  .  .  .  . . .  .  .  .  . .  . . . . . . . . . .  .  .  . .  . . .  . .  686
2.2.  Inclusion  criteria  . .  .  . . .  . . . . . . .  . . . .  . . .  .  .  . .  .  .  . .  . . .  .  .  . .  . . . .  .  . .  . .  .  . . . .  . .  . . . . . . .  .  . .  . . . . .  . .  . . .  .  .  . . .  . . . . .  . . .  . . . . . .  .  . . . . . .  .  . . . . . . .  . . . . . .  . .  .  .  .  .  . .  . .  .  . .  . 686
2.3.  Study  design  .  .  . . .  . . .  .  . . .  . . . .  . . .  .  . . .  . . . .  . . .  .  . . . .  . . .  . . . .  . . .  . . . . . . . .  .  . . .  . .  . . . . . . .  .  . .  . . .  . . . .  . . . .  .  . . . . . . .  . . . . . . .  . . . .  .  . . . .  .  . .  . .  .  .  . . . . . .  . .  . .  . .  .  .  .  .  .  . 686
2.4.  Study  review  .  .  . . .  .  . . .  .  . . .  .  . .  . . . . . . . . .  . .  .  . . . .  . . .  . . . . . . .  . . . . .  .  . . .  . . . . .  .  .  . . . . . . . .  . . . . .  . . .  . . . . . .  . . . . .  . . .  .  . . .  .  . . .  .  . . . . . . .  . . . .  . . . . . .  .  .  .  .  . .  .  .  . .  . . .  . . 686
2.5.  Data  extraction  and  quality  assessment  .  . . .  .  . . .  .  . . . . . .  .  . . . . . .  .  . .  . . . .  .  . . . . .  .  . .  .  . . . . .  .  . . . .  . . .  .  .  . .  .  . . . .  . . . . . . . .  . . . . .  .  . . .  .  .  .  .  . .  .  . . . . . . . . .  .  .  . .  .  . 686
2.6.  Data  synthesis  . .  .  . . .  .  . . .  .  . . .  .  . .  . . . . . . . . . . . .  . . . .  .  . .  .  . . . . . .  .  .  . . .  . .  .  . . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . .  . . .  .  . . . . . .  .  . .  . . . . .  .  . . . . . .  .  . .  .  .  .  .  . . . .  .  . . . . .  . .  .  . . . .  703
2.7. Zero-time  .  .  . .  .  . . .  .  . . .  . . .  . . . .  . . .  . . . .  .  . . .  . . . . . . . . . . .  . . . .  . . . . . . . . . .  .  . . . . . . . . . . . .  .  . . . . . . .  . . .  . . .  . . . .  . . . .  .  .  . . . .  . .  . . . .  . . .  .  .  .  . . .  .  . . . . .  .  .  .  .  . .  .  . . .  . . .  . . 703
2.8. Missing  data  .  . . . .  . . . . . . .  . . .  .  . . .  .  . . .  . . .  . .  .  .  . . .  .  . . .  .  . . .  .  . . .  . . .  .  . . .  .  .  . . . . . . .  . .  . .  .  . . .  . . . . . .  .  .  . . .  . . . .  . . .  . .  .  . . . . . . .  .  .  . .  .  . . . .  . . . . . . .  . . .  .  .  . . . .  .  . .  . .  . . 703
3. Results  . .  .  . . . . . . .  .  . . .  .  . . .  .  . . .  .  . . .  .  . . .  . . . .  . . . .  . . .  .  . . .  .  . .  .  .  . .  .  . . .  . . . .  . . .  .  . . .  .  . . . .  . .  . . . .  . .  . .  . . .  . .  .  . . . . . .  .  . . . .  .  . .  .  . . . . . . .  . . .  .  . . . .  .  .  . . . . .  . . .  .  .  .  . . . .  . . .  . . .  . . 703
3.1.  Literature  search  and  quality  assessment  .  . . .  .  .  . .  .  . . .  . . .  .  . . .  .  . .  . . . . .  . .  . . . . . .  .  . . . . . .  . . .  . . . . .  . . . . . . . . . .  . . .  . . . .  . . . . . . .  . .  .  .  .  .  .  . . . . . .  .  . .  .  . .  .  .  .  .  .  . 703
3.2.  Study  characteristics .  . . .  .  . .  . . . . . . .  .  . . .  .  . .  .  .  .  .  .  .  .  . .  . . .  .  . .  .  . . . . .  .  . . . .  . . . . . . . . .  .  . .  .  .  . . . . . .  . .  .  . . .  .  . . .  . . .  . . .  . . . .  .  . . . . . . .  .  . . .  .  .  . .  . .  .  . . . . . . . . . .  .  .  .  . .  706
3.3.  Studies  with  baseline  assessment  up  to one  month  post-injury  . . . . .  . .  . . .  . . .  . . . . . .  .  .  . . .  .  . .  .  . . .  . .  .  . . . .  . . .  . . . .  .  . . .  .  .  . . . . .  .  . . .  .  .  . . . .  .  . . . .  .  . . .  706
3.4.  Studies  with  baseline  assessment  after  one  month  post-injury  . .  . .  . . . . . .  .  . . . . . .  .  . . . .  . . . . .  . . .  . . . . .  .  .  . . .  .  . .  . . . . .  .  .  .  . . .  .  .  . . . . . . . . .  .  . .  . .  .  .  . . .  . 706
3.5.  Assessment  of TBI .  . . . . . .  .  . . .  .  . . .  .  . . .  . . . . . . . . . . . . . . . .  . . .  . . . . . .  .  .  . . .  . . . .  . . . .  .  . . . . . . . .  . . . . .  .  . . .  .  . . . . . . . .  . . .  . .  . . . . .  .  .  . .  . . . . .  . .  . . .  .  . . . . . .  . . .  .  .  .  .  . . 706
3.6.  Methods  used  for  assessing  fatigue  .  .  . . .  .  . . .  .  . . .  .  . . . . . .  .  . . . .  . . . . .  . . .  . .  .  . . .  .  . . .  . .  . . . . . . .  .  .  . . . .  .  . .  . . .  . .  . . . . .  .  . . . .  .  . . . .  .  . . . . .  . . . . .  . . .  .  .  .  .  .  . . . .  .  706
3.6.1. Multi-item  scales  . . .  .  . .  . . . .  . . . . . . . .  . . . .  . . .  .  . . . . . .  .  .  . . . .  .  . .  .  . .  . .  .  . . . .  . . .  . .  . . .  . . .  . . .  . . . .  .  . . .  . . . .  .  . . . .  . . .  .  . . .  . . . . . .  . . .  . .  .  . . .  . . . . . .  .  . . .  706
3.6.2.  Single  item  assessment  of  fatigue  . . . .  . . . . . . .  .  . . . . . .  .  . . . . . .  . . . . . . . . . .  . . .  . . . . . . .  . . .  .  . . . .  . . .  .  . . . . . . .  . . . . .  . .  . . . . . . . . . .  . . .  .  .  .  .  . .  .  .  . . . . . 707
3.6.3. Multiple  measures  of  fatigue  . . .  .  . .  .  .  . .  . . .  . . . . .  . . .  . . . . . .  .  . . . . . . . .  . . . .  .  .  . .  . . . . .  . . . . .  .  . . .  .  . . .  . . . .  .  . . . .  .  .  . .  . . . . . . .  .  . . .  .  .  . . . .  . . . . .  .  . . . . 707
3.7. Overall  predictors  of  fatigue  . .  . . . .  . . .  .  . . . .  .  . . .  . . .  .  . . . . . .  .  . . . . . .  . . . . . . . .  . . . . .  . . .  . . . . . .  . . . . .  . . .  . . . .  .  . .  . . .  . . . . . . .  .  . . . .  .  . . . .  .  . .  .  . .  .  . . . . . . . . .  .  . . .  . 707
3.8.  The  course  of  fatigue.  .  . . .  .  . .  . . . . . . .  .  . . . .  . . .  .  . . .  . . .  .  . . . . . . .  . . . .  . . .  . . . .  .  . . . . .  . . .  . . . .  .  . . . .  . .  .  . . . . . .  . . . . . . .  .  . . . .  . . .  .  .  .  . . . .  . . . . .  .  . . .  . .  .  . . .  . . . . . .  . .  707
3.9.  The  course  of  fatigue,  by injury  severity  . . . . . .  . . . .  . . . .  . . .  . .  . .  . . .  .  . .  . . . . .  . .  . . . . . .  .  . . . . . .  .  . . . .  .  . .  . .  . .  . . . .  . . . . . . . .  .  .  . . .  .  .  . . . . .  .  . . . .  . .  .  .  .  .  .  . .  .  .  .  707
3.10.  Fatigue  severity.  . . .  . . . .  . . . .  . . .  . . . .  .  . . .  .  . . . . . . . . . .  .  . . . . . .  .  . . . . . .  .  . . . . . . .  . . . . .  . . .  . . . . .  . . . . . . . . . . .  . . . . .  . .  . .  . . .  . . .  . . . . .  .  . . .  .  . . . . .  .  . .  .  .  .  .  . . .  . . . .  .  707
3.11.  Impact  of  fatigue  after TBI .  . . . .  . . . .  . . . . . . .  .  . . .  .  . . .  .  . . . . . .  .  . . . . . . .  . . . . . .  . . .  . . .  . .  . . .  . .  . . .  .  .  . . .  . . . .  .  . . . . . .  . . . . . . .  .  . . . . . .  .  . . .  . .  .  . . .  .  . . . . .  .  . . .  . . . 709
3.12.  Associations  of  fatigue  with  other  clinically  important  variables  .  . . . . .  . .  . . . . . .  .  . . . .  . . . . .  . . .  . . . . .  .  .  . . .  .  . .  . . . . .  .  .  .  . . .  .  .  . . . . . . . . .  .  . .  . .  .  .  . . .  . 709
3.12.1.  Studies  with  baseline  assessment  up  to one  month  post-injury  . . .  . .  . . .  .  .  . .  . . . .  . . . . . . .  .  . . . .  . . .  . . . .  . . . . .  .  . . .  .  .  .  . . .  .  . . . . .  .  . . .  .  .  . .  709
3.12.2.  Studies  with  baseline  assessment  after  one  month  post-injury  . . .  .  . . .  . . .  . . . . .  . . . . . . .  .  . .  . . . .  .  .  . . .  .  . . .  .  .  . . . .  . . . . .  .  .  . .  . .  .  . . . . . . .  . . 709
3.13.  Medications,  drugs  and  alcohol  .  . . .  .  . .  . .  . .  . . . .  . . . .  . . .  . . . . . . .  . . . .  .  . . . . .  . . .  . . .  . .  .  . .  . . .  . .  . . . . .  .  . .  . . . . . .  .  .  . . .  . .  .  .  .  . . . . .  . . . . .  . . . .  . .  .  . .  . . . . .  . . .  . . 710
4. Discussion  .  . . . . . . .  .  .  . . .  .  . . .  .  . . .  . . .  . . .  .  . . .  .  . . .  .  . . .  .  . . .  . . .  .  . . . . . .  .  .  . . . . .  .  . . . . . . .  . . . . .  . . .  . . . . .  . .  . . . . . . .  .  . . .  . . . .  .  . . .  . . . . . . .  . . . .  .  . . .  .  .  .  . . .  .  . . . . . .  . . .  .  .  .  .  . .  710
4.1.  Factors  associated  with  fatigue  . . . .  . . .  . . .  .  . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . . . . .  . . . .  .  . . . .  . .  . . . . . . .  . . . . .  . .  .  . . . .  . . .  . . . . .  . . .  .  . . . . . .  .  . . .  .  .  .  . . .  .  .  . . . .  .  . . .  . 710
4.2. Frequency,  severity  and course  of fatigue  in  TBI  . . . . . .  .  . . . .  . . .  . . . . . .  .  . . .  . .  . . .  . .  . . .  . . . .  .  . .  . . .  . . .  . . . .  .  .  . . . . . .  .  . . . . . . .  . . . . .  .  . . .  .  . .  . .  .  .  .  . . . . .  . . . 710
4.3.  Consequences  of  fatigue  in  TBI  . . . .  . . .  .  . .  .  .  . . .  .  . . .  . . .  .  . .  .  . . .  . .  .  . . .  . . .  .  . . . . .  . . .  . . . . .  . . .  . . . . . . .  . . . . .  .  . .  .  . . .  .  . . .  .  . . . . . . . . . .  .  .  .  .  . .  . . . .  .  . . . . . .  . .  . . 711
4.4.  Medication  effects  . . .  . . .  . . . .  . . .  .  . . .  .  . . .  . . . . .  . . . . . . .  . . . . . . . . . .  . . . . . . .  .  . . . . . . . . .  . . .  . . .  . . . . .  . . . . . . .  .  . . . . . .  .  .  . . . . . .  . . . .  . . .  . . .  .  .  . . . .  .  . . . . .  . . . .  .  . . .  711
4.5.  Limitations  .  . . . .  .  . . .  . . . . . . .  . . .  .  . . .  .  . . . .  . . . . . .  .  . . .  . . .  .  . . . . . .  .  . . . . . . .  .  . . . . . . . . .  . . .  . . .  . . . . . .  .  . . .  .  . . . .  .  . . . .  . . .  . . . . . .  .  .  . . . . . . . . . . . .  .  . .  . .  .  .  . .  . . .  . . . .  712
4.6. Pitfalls  and  controversies  . . . .  . . .  .  . . .  .  . .  .  .  . .  .  .  .  . .  . . . .  .  . .  . . . .  . . . . . . .  . . .  .  . .  . . . . .  . .  . . .  .  .  . .  .  . . .  . .  . . . . . .  . . . . . . .  .  . .  . . . . .  . . . . .  . . .  .  . . . . . . .  . . . .  .  .  .  .  . .  .  .  712
5.  Conclusions  . . .  . .  .  . .  . . . . . .  .  . . .  .  . . . .  . . .  .  . . .  .  . . . . . . . .  . . . . . .  .  . . . . . .  .  . . . .  .  . .  . . . . . . .  . . .  . . . . .  .  . . . .  . . . . . . . . . .  . . .  .  . . . .  . . . . . . . . . . . . . .  .  . . .  .  .  . .  . .  .  . . .  .  .  . . . .  . .  . . . . 714
Authors’  contributions  . .  . . .  .  . . .  . . . .  .  . . .  .  . . . . . . . . . . . . . . . . . .  . . . . . . .  .  . . . .  .  . .  .  . . . .  . . .  . . .  . . .  .  . . .  . . .  . . .  . . . . . . .  . . . . . . . .  . . . . . .  .  .  . . .  . . .  . .  . . . . . . .  . . .  . .  .  .  . . .  .  . .  714
Acknowledgements  .  . . .  .  . . .  . . .  .  . . . .  .  . . .  .  . .  . . . .  .  .  . .  .  . .  .  .  . . . . . .  .  . . . . . . . . . . .  .  . .  . . .  . . . . . . .  . . .  . .  .  . . . .  . . . .  . . . . . . .  . .  .  . . .  . .  . .  . . .  .  .  . . . . .  . . . .  .  . . .  .  .  .  . . . . . . .  .  . .  714
Appendix  A.  Supplementary  data  .  . . . .  . . . .  . . .  .  . . .  .  . .  .  .  . .  .  .  . . .  . . .  .  .  . .  . . . . .  . . . . . . .  . . .  . . . . .  . . .  . . . . .  . . .  . . .  . . .  .  . . . .  .  . . .  . . .  . . .  .  . . . .  . . .  .  .  .  . . .  . . . . . . . .  . . . 714
References  . .  . . . . .  .  .  .  . .  .  .  . . . . . .  . . . .  . . . .  . . .  .  . . .  .  . .  .  .  .  .  .  .  .  . .  .  . .  .  . . .  .  . . . . . . .  .  . . . . . .  . . .  . . . . .  . . . . .  . . .  . . . . .  . . . . . . . .  . .  . . .  .  .  . . .  . . . . .  .  .  . . .  .  .  .  . . .  .  . . . . . .  . . .  .  .  . .  . 714
. Background
Traumatic brain injury (TBI), deﬁned as “an alteration in brain
unction, or other evidence of brain pathology, caused by an exter-
al force” (Brain Injury Association of America, 2013), is among
he most serious, disabling neurological disorders in all societies
nd expected to rank as the major cause of death and disability
y the year 2020 (World Health Organization, 2002). Over the past
ecades, evidence has emerged citing fatigue as a common, long-
asting problem after TBI (Belmont et al., 2006; Ponsford et al., 2011;
iddleboe et al., 1992). It is burdensome to patients, and is asso-
iated with poor outcomes (Belmont et al., 2006; Ponsford et al.,
011). In a number of studies, over half of the patients making up
he TBI samples reported fatigue’s negative effect on social, physical
nd cognitive functioning (Ziino and Ponsford, 2006) and participa-
ion in everyday activities (Cantor et al., 2008), and role in increased
ork-related and other disabilities (McCrimmon and Oddy, 2006).
The term “fatigue” has several meanings. It is recognized when
performance of an activity results in diminished capacity for car-
rying out a function (Chaudhuri and Behan, 2004). Within this,
‘physiological fatigue’ refers to the state of general tiredness due
to physical or mental exertion, which can be ameliorated by rest
(Schillings et al., 2007). A state that refers to a weariness unrelated
to previous exertion level, and not ameliorated by rest, is termed
‘pathological fatigue’ (Jason et al., 2010). Despite such characteri-
zation, fatigue in the TBI population is difﬁcult to elucidate. This is
partly due to the numerous plausible biological causes of fatigue
(i.e. neuroanatomical, functional, psychological/psychiatric, bio-
chemical, endocrine, sleep-related), independently or combined,
through which this symptom can evolve after brain injury (Fig. 1)
(Prins et al., 2006). To date, several narrative reviews have been
published to provide insight into the topic of post-traumatic fatigue
(PTF) (Belmont et al., 2006; Borgaro et al., 2005; Ponsford et al.,
2012; Levine and Greenwald, 2009). Nevertheless, there is still littlestimates of the incidence of fatigue after TBI vary from 21% to
3%, depending on the characteristics of the studied population
e.g. severity of injury, time since injury, sampling of patients, etc.)
nd the method used to identify fatigue (e.g. single item or fatigue
cales) (Belmont et al., 2006; Ponsford et al., 2011; Middleboe et al.,
992; Borgaro et al., 2005; Lidvall et al., 1974).known about which speciﬁc clinical, behavioral and physiologi-
cal factors are associated with its occurrence after brain injury;
nor whether fatigue remains the same in its frequency/intensity,
or changes over time. Finally, the overall health burden of this
symptom in the TBI population remains uncertain. Understand-
ing the facets of fatigue in TBI can guide in differential diagnosis
686 T. Mollayeva et al. / Neuroscience and Biobehavioral Reviews 47 (2014) 684–716
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nd follow-up treatments. Moreover, identifying the most impor-
ant contributors to PTF can change the view on the interventions
ecessary to deal with this signiﬁcant symptom. This systematic
eview was performed with the following goals, all with respect to
atients with TBI: (1) to determine the prognostic factors associ-
ted with fatigue onset; (2) to describe the course of fatigue; and
3) to describe the health consequences of fatigue.
. Methods/design
.1. Data sources and searches
This review was conducted and reported in compliance with
he Preferred Reporting Items for Systematic Reviews and Meta-
nalyses (PRISMA) guidelines (Moher et al., 2009). The systematic
eview protocol was registered with the International Prospec-
ive Register of Systematic Reviews (PROSPERO) (Mollayeva et al.,
013a) on April 25, 2013 (registration number CRD42013004262).
In collaboration with disease experts and a medical informa-
ion specialist, we developed a comprehensive search strategy for
tudying fatigue in TBI (Mollayeva et al., 2013a). All English lan-
uage peer-reviewed studies with prospective or retrospective data
ollection and a longitudinal design, found through PsycINFO, MED-
INE, EMBASE and CINAHL, published since 1806, 1946, 1974 and
980, respectively, were eligible. Cochrane Database of Systematic
eviews was also searched for studies published between 2005
nd early April 2013. Publications identiﬁed from bibliographies
f identiﬁed articles and reviews were considered eligible. The
asic search can be found in Supplementary File 1. For the com-
lete search strategy, we refer the reader to the published protocol
Mollayeva et al., 2013a).
.2. Inclusion criteria
Peer-reviewed, English language studies that investigated
atigue in adult patients with a diagnosis of TBI and followed them
or any period were included. Studies that focused on a different
ut parallel topic to fatigue (e.g. sleepiness, impaired alertness,
r vigilance) and studies about fatigue after brain injury due to
econdary pathological processes (e.g. edema, intracranial hemor-
hages, ischemia/infarction, and systemic intracranial conditions) traumatic brain injury.
 al. (2013).
were excluded. Further, case reports, pediatric studies, disserta-
tions, and articles with no primary data were excluded. For more
information, we  refer the reader to the protocol (Mollayeva et al.,
2013a).
2.3. Study design
All experimental intervention and effectiveness studies of longi-
tudinal design and observational cohort- and case control-designed
studies were considered for this review.
2.4. Study review
In the ﬁrst stage of screening, two  reviewers (TM and TK or TM
and SM)  assessed study titles and abstracts for possible agreement
with the inclusion criteria. In the second stage, each reviewer indi-
vidually assessed the full text of articles selected in the ﬁrst stage
to determine whether they met  inclusion criteria. Differences of
opinion were resolved by discussion between reviewers, or by seek-
ing advice from other experts (AC, CS, and JDC). Studies failing to
meet the inclusion criteria were excluded, with reasons listed in
Supplementary ﬁle 2.
2.5. Data extraction and quality assessment
The abstracted data included: (1) study characteristics (i.e.
author names, publication year, country, setting, design, sample
size, methods of measuring fatigue, and other variables [e.g. fac-
tors], number of participants assessed at each time point, time
between assessments, and time from injury to follow-up); (2)
participant characteristics (i.e. mean age, sex, deﬁnition of TBI,
localization of injury, and injury severity); (3) medications used
by or administered to participants; and (4) results (i.e. reported
frequencies of fatigue and other factors, and reported associations
between fatigue and other variables) (Tables 1–3).
For studies that fulﬁlled the inclusion criteria, two reviewers
(TM and TK) independently extracted data into data collection
forms grouped according to study design. The observational stud-
ies’ data were used to address the three research objectives (i.e.
prognostic factors, course of fatigue, and consequences). Random-
ized control trials (RCTs) were treated as cohorts, and the control
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Table 1
Summary of study characteristics, including details on study sample, design, methods and results pertaining to fatigue.
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Bushnik et al. (2008a)
US
Medical center
inpatient rehabilitation
Preliminary ﬁndings from
study of fatigue in individuals
with mod-sev TBI 2 yrs
post-injury; document change
in nature of fatigue over time,
assess contributing factors
Prospective longitudinal
F/U: 6, 12, 18–24 mos
post-injury
IC: inpatient rehabilitation;
TBI; ≥18 yrs at injury;
speak/write/read English;
informed consent
EC: conditions associated with
fatigue
n  = 51
Attrition: 0
Age: 31 ± 13
Sex: 76% M
TSI: discharge – 6 mos
post-injury
IS: GCS motor; PTA length;
degree cranial midline
shift: mod-sev
AT: baseline
t1: 2.6 ± 1.8 mos
t2: 12.6 ± 1.2 mos
t3: 23.2 ± 3.4 mos
rmANOVA: change
over time
Post hoc pairwise t
tests: signiﬁcant
variables
p-value = .01
NR*
*Study #2, same
population: at year 1 –
11% illicit drug users,
19% classiﬁed as
problem substance
users; at year 2 – 29%
classiﬁed as problem
substance users
BFS: synthesis of items from
other scales: MAF, FSS, FAI, FIS,
GFS
BFS: higher scores = greater
fatigue
From BFS: scores for Global
Fatigue Index (GFI) of MAF  and
FSS: higher scores = greater
fatigue
Scores: t1, t2, t3:
BFS subscales (n = 46*):
Intensity: 36 ± 17; 30 ± 19;
33 ± 18
Activities of daily living:
33 ± 18; 28 ± 18; 32 ± 21.5
Socialization: 24 ± 14; 20 ± 13;
22 ± 15
Mental functioning: 25 ± 12;
20 ± 12; 21 ± 12
General impact: 11 ± 7; 9 ± 6;
10 ± 6
Relieving factors: 16 ± 8;
15 ± 8; 18 ± 6
Aggravating factors: 21 ± 14;
18 ± 11; 21 ± 10
GFI (n = 43*): 23 ± 10; 17 ± 11;
20 ± 11
FSS (n = 45*): 3.4 ± 1.5;
2.9 ± 1.6; 3.2 ± 1.8
*Missing data, unanswered
questions
Score changes:
BFS subscales: NS
GFI: signiﬁcant
decrease t1 − ct2
(t42 = 5.4; p = .0018;
effect size = .58)
FSS: NS
Notes:
Fatigue total scores had
same pattern of
change: highest at t1,
lowest at t2, slight
increase at t3
GFI at t1: only score
comparable to other
populations with
signiﬁcant fatigue
BFS subscales:
low-mod fatigue; avg
scores below 50% of
max  score for each
subscale (exception:
relieving factors)
Associations:
Increased fatigue
t1 − t2, more sleep
problems (PSQI)
decreased and stable
fatigue scores,
decreased PSQI
Increased fatigue,
decreased cognitive
functioning; decreased
fatigue-increased
cognitive functioning;
similar for general
functioning, motor
symptoms
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Table 1 (Continued)
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
De Leon et al. (2009)
US
Level II community
hospital ED
Compare fatigue reports of
participants 12 mos  post-MHI
with those with other injury by
mild trauma; injury, BL
predictors of fatigue
Inception, cohort
F/U: 12 mos
IC: presented directly to ED w/I
24 h of injury; ≥18 yoa;
GCS ≥ 13; did not meet criteria
for activation of adult trauma
team; discharged directly from
ED; competency for informed
consent; mini-mental state
examination ≥18; able to
describe essential elements of
study
EC: transfer from other
hospital; non-English
speaking; being incarcerated;
medical evaluation resulting in
admission; state of PTA at
recruitment; LOC ≥ 30 min;
LOC not attributable to trauma
n = 359 (w/  12 mos  data)
3 groups: 1: HI w/ PTA
&/OR LOC; 2: HI only; 3:
other injury (n1, n2, n3)
n1 = 58, n2 = 173, n3 = 128
* No medical info wrt
occurrence of brain injury
Attrition: 31.9%
Age: NR
Sex:
1: 44.8% M
2: 41% M
3: 43.7% M
TSI: 12 mos
IS: mild
AT: BL/n = 504
t1: 1 mos  (NR)
t2: 3 mos  (NR)
t3: 12 mos/n = 359
2-tailed tests of
signiﬁcance, ˛ = .05
Chi-square: group
differences
(categorical)
Univariate ANOVA:
group differences
(continuous)
Hierarchical linear
regression: variable
associations
NR MOS  SF-36 Vitality subscale
Low scores on vitality subscale
indicate more fatigue
Mean SF-36 vitality subscale
scores at BL:
1: 52.8 ± 9.5
2: 50.4 ± 10.5
3: 53.4 ± 8.6
*HI only group (2): greater
fatigue severity (p = .026)
t3:
1: 52.3 ± 12.2
2: 49.6 ± 11.8
3: 53.0 ± 10.4
*Signiﬁcant differences
between groups (F2,356 = 3.77,
p  = .024, partial 2 = .02)
Pair-wise comparisons:
1: Lower mean score at
12 mos than other
injury group (p = .027)
2: Comparison NS
Driver and Ede (2009)
US
Community
Changes in mood in response
to 8 wk physical activity (PA)
intervention
Stratiﬁed random sampling
F/U: 8 wks
IC: >level 6 Ranchos Los
Amigos Scale of Cognitive
Functioning; TBI > 1 yr prior;
outpatients at rehabilitation
center
EC: NR
n = 18 TBI
2 groups: 1: PA; 2: control
Attrition: 0
Age: 37.7 ± 2.3
Sex: NR
TSI:
1:40.8 ± 14.7 mos
2:36.3 ± 14.2 mos
IS:
Each group: 6 w/ left-sided
lesion proximity to frontal
pole; 1: 2 w/ damage to left
basal ganglia; 2:
2  w/damage to right
parietal occipital lobe
AT: BL
t1: 8 wks
ANOVA: between,
within group
differences
Effect size: total
variance accounted for
by independent
variable
1: 5 taking SSRIs for
duration of program*
2: 6 taking SSRIs for
duration of program*
*Not as part of study
Fatigue deﬁnition: NR
POMS fatigue-inertia subscale
Mean fatigue subscale scores at
BL:
1:  1.4 ± 1.1
2: 1.2 ± .6
Mean fatigue subscale scores at
t1:
1: .5 ± .6
2: 1.3 ± .6
Effect size:
1: 1.00
2: .08
Within group
differences (BL − t1):
1: signiﬁcant (F = 4.7,
p < .05)
2: NS
Between group
differences:
Fatigue NR; signiﬁcant
wrt total POMS score
(F = 5.7, p < .05)
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Gemmell and Leathem
(2006)
NZ
Psychology clinic, head
injury society
Whether Tai Chi would have
immediate effect on mood
states in TBI group;
improvement of perceived
physical, emotional functions,
self-esteem, social functioning,
health over time
Within-group, between-group
with control
F/U: 6 wks
IC: mild, mod, severe TBI on
basis of
retrograde/anterograde
amnesia, PTA, and/or LOC with
associated outcomes
EC: NR
n = 18
2 groups: 1: Tai Chi (9); 2:
control, waiting list for Tai
Chi (9)
Attrition: 0
Age:
F:  40.2 ± 12.5, M:
51.2 ± 8.7, Sex: 50% M
TSI: mean = 8.7 yrs
IS: NR
AT: Before
t1: After (6 wks)
t-tests: within,
between group
differences at time
points
ANOVA: within,
between group
differences over time
periods
NR Fatigue deﬁnition: NR
MOS  SF-36 Vitality subscale
VAMS Tired mood state scale
(Tai Chi group only)
SF-36 Vitality: Before:
1: 47.1 ± 18.2
2: 47.5 ± 20.2
After:
1: 40.7 ± 22.3
2: 38.8 ± 4.4
VAMS Tired: Before:
1: 54.4 ± 6.0
After:
1: 52.5 ± 5.8
SF-36 Vitality: Before:
1 vs. 2: NS (t = −0.04)
After:
1 vs. 2: NS (t = 0.25)
VAMS:
1: Fatigue NS (t = 1.10)
Hou et al. (2012)
UK
ED
Optimal early predictors for
post-concussional syndrome
(PCS) following mild TBI
(mTBI); cognitive, emotional,
behavioral, social perpetuating
factors in development of PCS
Prospective cohort
F/U: 3, 6 mos
IC: 18–60 yoa, mTBI
EC: multi-trauma requiring
hospitalization, major
neurological/psychiatric
disorders
n = 126
Attrition: 25%
Age: 38.3 ± 14.1
Sex: 63% M
TSI: ≤2 wks
IS: GCS: mild
AT: BL: ≤2 wks
post-injury/n = 126
t1: 3 mos/n = 107
t2: 6 mos/n = 107
t-tests, chi-square:
demographic, clinical
characteristics
Individual regression
analyses: cognitive,
emotional, behavioral
variables as covariates
with gender/age, PCS
outcome as dependent
variable
Logistic regressions
(LR): for signiﬁcant
variables from
individual regression
analyses
Stepwise backward LR:
derive models for 3, 6
mos
Hosmer–Lemeshow
‘goodness of ﬁt
statistic’: ﬁt of model
assessment
NR Fatigue deﬁnition: NR
RPQ (including fatigue, sleep
disturbance items)
RPQ: fatigue, sleep disturbance
– most commonly reported
symptoms are 3 and 6 mos
port-mTBI
Fatigue frequencies: NR
From bar graph:
Fatigue at 3 mos  ≈33%, at 6
mos ≈28%
Sleep disturbance at 3 mos
≈27%, at 6 mos ≈24%
NR
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Table 1 (Continued)
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Hutchinson et al.
(2009)
CA
University sports
Determine whether athletes
with concussion and those
with musculoskeletal injuries
(MSI) differed in emotional
responses post-injury;
differences in BL emotional
status in 3 groups: mTBI, MSI,
active control (CTL) (control for
premorbid emotional
disturbance)
Prospective longitudinal cohort
F/U: 1,2,3 d
IC: university athletes in sport
with risk of concussion
EC: self-reported at
neuropsychological
assessment: >5 concussions;
learning disability; psychiatric
disorder
n = 53
3 groups: 1: mTBI (20); 2:
MSI (14); 3: CTL (19)
Attrition: 0
Age:
1:  20.1 ± 1.8
2: 19.2 ± 2.3
3: 21.6 ± 1.6
Sex:
1: 60% M
2: 86% M
3: 47% M
TSI:
1: ≤96 hrs
IS:
1: concussion (mTBI) by
team physicians, therapists
AT: BL
t1, t2, t3: 3 d*
*Nonconsecutive over 2
wks
Descriptive:
demographic variables,
mood scales
Cronbach alpha: scale
reliability
ANOVA: group
differences on POMS
subscales at BL;
physical characteristics
Student–Newman–Keuls
multiple-range test
(.05): F/U means
Tukey–Kramer
correction for type I
error
NR Fatigue deﬁnition: NR
POMS fatigue subscale:
Reliability: .863
Scores:
Main effects: NS
Signiﬁcant interacting effect
for fatigue (F(6, 150), 10.11;
p < .001)
Difference at t1:  signiﬁcant for
1 (increase) vs. 2, 3
POMS fatigue subscale:
Difference BL − t1:
signiﬁcant for 1
Notes:
1: signiﬁcantly greater
fatigue, lack of energy
(POMS vigor subscale)
post-injury
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Jha et al. (2008)
US
Hospital
Efﬁcacy of modaﬁnil for
treating fatigue, excessive
daytime sleepiness (EDS) in
persons with TBI; hypothesis:
modaﬁnil more efﬁcacious
than placebo; outcomes wrt
cognitive function, health
related quality of life
Single-center randomized
blinded, placebo-controlled
cross-over
F/U: 4, 10 wks
IC: 1-year post-TBI; 18–65 yoa;
received inpatient
rehabilitation at single model
system of care
EC: presence of
neurologic/neuropsychiatric
diagnosis; diagnosis by history
of other likely causes of EDS;
concurrent medication use
and/or clinically signiﬁcant
systemic disease that might
cause fatigue/diminished
arousal; epilepsy;
cardiovascular
disease/hypertension requiring
medical tx; history of severe
renal/hepatic impairment;
signiﬁcant
psychiatric/behavioral
disturbance; non-English
speaking; pregnant females/of
childbearing potential
n = 51 (46*)
2 groups: 1: modaﬁnil ﬁrst
(27 (22*)); 2: placebo ﬁrst
(24)
*5 participants in group 1
withdrew
Demographic/clinical
characteristics reported for
n = 51**
**NS imbalances to affect
trial results
Attrition: 0
Age: 38.3 ± 12.2
Sex: 69% M
TSI: 5.8 ± 5.0 yrs
IS: GCS: mild (25.5%), mod
(23.5%), sev (51%)
AT (n = 46): BL
t1: wk  4
t2: wk  10
t-tests, chi-square:
continuous and
categorical,
respectively: BL
differences in
demographic/clinical
characteristics
between groups
Paired t-test: crude tx
effects
2-sample t-tests:
within group tx effects
Linear mixed-effects
regression: 4-wk
change in each of 2
periods for all
participants
Secondary analyses: tx
effects on secondary
end-points and at 10
wks
Modaﬁnil (≥400 mg)
Concurrent medication
use in exclusion criteria
MFIS
FSS
SF-12 (fatigue item)*
*Fatigue NR separately
FSS, MFIS high scores
Scores: BL; t1; t2:
FSS:
1: 45.2 ± 11.8; 39.4 ± 15.6;
37.13 ± 18.33
2: 44.46 ± 12.17; 37.7 ± 12.55;
36.91 ± 14.08
MFIS:
1: 46.56 ± 19.28;
38.65 ± 16.09; 35.63 ± 20
2: 47.17 ± 15.53;
36.45 ± 15.03; 33.55 ± 18.16
Group medication switch –
modaﬁnil to placebo, vice
versa:
FSS:
1  (placebo): 35.92 ± 16.82;
33.74 ± 16.16; 30.95 ± 16.25
2 (modaﬁnil): 38.17 ± 15.23;
31.38 ± 10.66; 28.90 ± 14.03
MFIS:
1: 36.27 ± 17.67;
37.74 ± 17.51; 31.20 ± 19.44
2: 39.73 ± 20.82;
28.91 ± 19.06; 28.27 ± 16.06
1 vs. 2:
modaﬁnil-placebo
scores:
Change wk 4-BL (p
value):
FSS: 2.33 ± 12.96 (.54)
MFIS: 5.68 ± 14.79 (.21)
Wk  10-BL:
FSS: .44 ± 15.31 (.92)
MFIS: 4.03 ± 16.93 (.43)
Group medication
switch – modaﬁnil to
placebo, vice versa:
Wk  4-BL:
FSS: −2.55 ± 11.07 (.45)
MFIS: −10.9 ± 15.93
(.03)
Wk 10-BL:
FSS: −3.70 ± 14.60 (.43)
MFIS: −8.07 ± 16.61
(.14)
Notes:
Participants suggested
fatigue measures used
in study do not
accurately reﬂect
fatigue experienced by
persons with TBI
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Table 1 (Continued)
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Kaiser et al. (2010)
CH
Hospital neurology
department
Effect of modaﬁnil on
posttraumatic EDS and fatigue
Prospective, double-blind,
randomized,
placebo-controlled, pilot
F/U: 6 wks
IC*: presence of
fatigue/EDS/both since injury
* Patients from earlier study
(Baumann et al., 2007)
admitted for closed mild-sev
TBI to surgical intensive care
unit
EC: patients with neurologic,
psychiatric, other disorders,
medications that may  cause
SWD; signiﬁcant SWD  other
than posttraumatic vigilance
impairment at BL; chronic
sleep deprivation
n = 20
2 groups: 1: modaﬁnil
(10); 2: placebo (10)
Attrition: 0
Age:
1:  37 ± 9
2: 43 ± 19
Sex:
1: 80% M
2: 90% M
TSI:
1: 1.8 ± .9 yrs
2: 2 ± 1.2 yrs
IS: GCS: mild-sev
AT: BL
t1: 6 wks
Pearson, Spearman
correlation analyses;
two-tailed t-tests;
Mann–Whitney U
tests; multivariate
regression analyses
Modaﬁnil
(100–200 mg)
Interfering medication
use as part of exclusion
criteria; caffeine, other
drugs not allowed
during course of study
FSS > 4
BL: frequency of fatigue
diagnosis:
1: .8
2: .8
BL: FSS
1: 5 ± 1.4
2: 4.6 ± .8
t1 (p = 0.07):
1: −.8 ± 1
2: .0 ± .6
Notes:
Overall subjective
estimation of vigilance
impairment
amelioration:
1: much better (0%);
better (30%);
somewhat better
(30%); unchanged
(30%); worse (10%)
2: much better (10%);
better (10%);
somewhat better
(10%); unchanged
(70%); worse (0%)
Kempf et al. (2010)
CH
University neurology
department
Prevalence, characteristics of
post-traumatic sleep-wake
disorders (SWD)
Prospective, longitudinal,
clinical
F/U: 3 yrs
IC: acute, ﬁrst TBI; no SWD,
psychiatric/neurological
disorders prior; admitted
immediately after injury
EC: NR
n = 51
*Studied at 6 mos  wrt  SWD
(n = 65, Baumann et al.,
2007)
Attrition: 21.5%
Age: 40 ± 16
Sex: 84% M
TSI: 3 yrs
IS: GCS: mild (42%), mod
(22%), sev (38%)
AT:
t1: 6 mos/n = 65 (Baumann
et al., 2007)
t2: 3 yrs/n = 51 (this study)
Correlation analyses
t-tests: parametric
Mann–Whitney U
tests: non-parametric
One-way ANOVA:
group differences
McNemar test: 
repeated dichotomous
measures
3  (antiepileptic drugs),
1 (zopidem for sleep)
Fatigue Severity Scale (FSS)
FSS ≥ 4
t1: 17%
t2: 35%
51%: fatigue associated
symptoms (daytime tiredness,
lack of energy, exhaustion)
since injury
NR
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Khateb et al. (2005)
CH
University hospital
neurology clinic
Whether patients with
cognitive/behavioral
impairment after brain injury
would beneﬁt from donepezil;
improvement would concern
one cognitive domain more
than others
Intervention
F/U: 3 mos
IC: outpatients of neurology
clinic; informed consent;
history of mod-sev TBI for ≤6
mos
EC: history of previous CNS
injury/disease; ongoing
drug/alcohol abuse; severe
speech/language disorders;
unstable psychiatric disorders;
compliance difﬁculties; use of
AchE inhibitors
n = 10
Attrition: 33.3%
Age: 43 ± 8
Sex: 60% M
TSI: 42 ± 33 mos
IS: PTA: 8 ± 10 d
AT: BL
t1: 3 mos
Non-parametric
Wilcoxon: statistical
signiﬁcance of changes
by donepezil therapy
Donepezil (5–10 mg)
Ongoing alcohol/drug
abuse, current use of
acetylcholine AchE
inhibitors as part of
exclusion criteria
Fatigue disability measured by
29-item fatigue scale: severity,
speciﬁcity, psychological
consequences, effects of
sleep/rest on fatigue
Fatigue scale high score –
severe symptoms
BL: mean score: 132.6 ± 27.3
t1: mean score:
126.1 ± 32.3 (p = .92,
Z = .10)
Notes:
Subjects’ self-report
post-tx: 80% reported
medication-related
improvement in ≥1
cognitive/affective-
behavioral domain –
40% wrt fatigue –
dominating
improvement
Subjective fatigue
improvement did not
correlated with
decrease in fatigue
score – only 2 patients
showed notable
decrease in score
2 patients that did not
report subjective
improvement had
notable decrease in
fatigue score
Discrepancies may be
result of varying
deﬁnitions of fatigue
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Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Lidvall et al. (1974)
SE
EDs
Establish whether PCS were
experienced only after injury,
or whether the patient was
already suffering them before
the trauma; explore the
etiology of the PCS
Prospective longitudinal cohort
F/U: 2, 6, 14, 30, 90 d
post-injury
IC: cerebral concussion (CC);
PTA; hospital emergency
admission ≤24 and
examination on the second d
after injury; ≤15; able to
cooperate; not required
surgical tx; good knowledge of
Swedish
EC: with mental or comatic
illness; alcoholics and drug
addicts
n  = 100 CC
Attrition: 0
Stats:
PTA (min):
<1: 17%; 1–5: 34%; 6–45:
29%; >45: 20%
Age: 33 y (av)
Sex: 69% M
TSI: <24 h
IS: PTA: mild-sev
AT: post-injury:
t1: 2 d
t2: 6 d
t3: 14 d
t4: 30 d
t5: 90 d
Descriptive: summary
of all variables
Chi-square: discrete
variable differences
between PCS- and
C-groups
Phi coefﬁcients for
symptoms clustering
NR PCS-symptom questionnaire
Fatigue frequencies by PCS list:
t1: 7%
t2: 5%
t3: 10%
t4: 8%
t5: 10%
Fatigue frequency at any given
time point – 12%
Clusters unstable,
varying in extent and
character across time
points:
t1:
1: headaches,
dizziness, fatigue,
concentration
impairment (largest)
2: memory
impairment, sensitivity
to light
t2:
1: headaches, dizziness
2: headaches, fatigue
3: dizziness, fatigue
t3:
1: headaches, fatigue,
dizziness
2: anxiety,
concentration
impairment
t4:
1: anxiety, fatigue,
headaches
t5:
1: headaches, anxiety
2: dizziness,
concentration
impairment
3: fatigue, anxiety
4: fatigue, headaches
Lundin et al. (2006)
SE
EDs
Report character, frequency,
course of persisting symptoms
and their relation to disability
through effects on daily
activities in mTBI patients
Prospective cohort
F/U: 1, 7, 14 d, 3 mos
post-injury
IC: blunt head trauma; LOC
and/or PTA; hospital admission
≤24 h post-injury; GCS 14–15
at ED assessment; 15–65 yrs
EC: LOC ≥ 30 min; PTA ≥ 24 h;
other signiﬁcant physical
injury/major neurological
disorder
n  = 102 mTBI; 35 controls
Attrition: 16.4%
Stats for TBI:
Age: 37.3
Sex: 58% M
TSI: 24 h
IS: GCS: mild
AT: post-injury:
t1: 1 d
t2: 7 d
t3: 14 d
t4: 3 mos
Mann–Whitney U
tests: non-normal
continuous data
Chi-square/Fisher’s
exact tests: categorical
data
Bonferroni adjustment:
multiple comparisons
p  = .05
Multilevel logistic
regression:
relationship between
stable patient
characteristics and
multiple
measurements
NR Rivermead Post-Concussional
Questionnaire (RPQ);
Rivermead Head Injury F/U
Questionnaire (RHFUQ*): both
feature fatigue item
*Administered only at t4
RPQ score classiﬁcation:
symptom resolution (1); mild
(2); moderate (3); severe (4)
RPQ fatigue frequencies:
t1: mTBI: 66.8%
(calculated from symptom load
bar graph)
t4:
mTBI: 21%
Control: 11%
t1–t4: signiﬁcant
decrease
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McLean et al. (1993)
US
Medical Center
Investigate type of
psychosocial difﬁculties
associated with head injury
(HI) at 1mos and 12 mos
post-injury; whether degree of
psychosocial impairment
relate to HI severity
Prospective cohort
F/U: 1 mo,  12 mos  post-injury
IC: HI; LOC and PTA > 1 h, or obj
evidence of cerebral trauma;
trauma required hospital
admission; 15–60 yrs
EC: previous CNS insult or
involvement (e.g. epilepsy, HI,
alcoholism, mental
retardation); psychiatric
disorder
n  = 102 HI; 102 controls
Attrition: 0
Stats for HI:
Age: 26.33
Sex: *primarily single M
TSI: 24 h
IS: GCS: mild – 58%; mod  –
11%; sev – 28%
AT: post-injury:
t1: 1 mos
t2: 12 mos
2 by 2 Chi-square tests
Mann–Whitney U tests
comparison of change
with time
Kruskal–Wallis
distribution-free
analysis of variance;
post hoc comparison
according to Tukey’s
method for
unequal-sized groups
NR
Prior history of
epilepsy, alcoholism,
mental retardation as
part of exclusion
criteria
The Head Injury Symptom
Checklist
Frequencies:
t1: 74%
t2: 47%
A signiﬁcant reduction
in the number of
fatigue endorsed from
1  mo to 12 mos
post-injury (p < .001)
Signiﬁcant difference
between cases and
controls at 1 mo  but
not at 12 mos
post-injury
Meares et al. (2011)
AU
Level 1 trauma hospital
Investigate course of PCS,
PCS-like symptoms;
relationship pre-injury,
injury-related, post-injury
factors to PCS development
Prospective
F/U: 3 mos  since hospitalized
IC: trauma center patient;
traumatic nonbrain
injury/mTBI; hospital
admission ≤24 h post-injury;
ﬁrst assessment ≤14 d
post-injury; 18–65 yrs;
IQ ≥ 70; adequate
understanding of English
EC: mod-sev TBI/intracranial
lesion; self-harm physical
injury; psychotic; history of
cognitive impairment;
medically unstable;
interstate/overseas visitor;
pregnant
EC at 3 mos: >5 mos
post-injury at F/U; inadequate
effort on testing by failure on
memory test
n = 62 mTBI; 58 TC
Attrition: 0
Stats for TBI:
Age: 35.7 ± 14.5
Sex: 67.7% M
TSI: 4.8 ± 3.1 d
IS: GCS: mild
AT: post-injury:
t1: ≤14 d
t2: 3 mos
Mann–Whitney U
tests: non-normal
continuous data
Chi-square/Fisher’s
exact tests: categorical
data
Bonferroni adjustment:
multiple comparisons
p  = .05
Multilevel logistic
regression:
relationship between
stable patient
characteristics and
multiple
measurements
Opiate administration
at t1/t2 (n):
mTBI (37/62)
Control (37/58)
Marijuana use:
mTBI: 24.4%
Control: 19%
AUDIT alcohol screen –
mTBI = 6.4 ± 6.8; ≥8 –
hazardous alcohol use
indicator
At least 1 subs use
disorder: 12.5%
PCSC: adapted version
including fatigue symptom
PCSC symptoms: 5-point scale;
clinically signiﬁcant if scored
as ≥3, indicating “often” for
frequency
Fatigue symptom frequencies
(≥3 on PCSC):
None:
mTBI: 40.3%
Control: 20.7%
Present at t1 and t2:
mTBI: 21%
Control: 32.8%
Present at t2 only:
mTBI: 14.5%
Control: 15.5%
Fatigue symptom
frequencies (≥3 on
PCSC):
Absent at t2:
mTBI: 24.2%
Control: 31%
Difference in frequency
between mTBI and
controls in
presence/absence at
t1/t2 of fatigue: NS
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Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Mickeviciene et al.
(2004)
LT
Hospital emergency
ward
Investigate PCS symptoms,
effects of sociodemographic
factors and expectations on
symptoms
Prospective controlled cohort
F/U: 3 mos, 1 yr post-injury
IC: admitted for head trauma
(w/ LOC) evaluation/tx; LOC
≤15 min
EC: history of drug/alcohol
abuse, epilepsy, signiﬁcant
psychiatric/neurological
disorder; previous concussion;
concussion-related seizures;
focal neurological signs,
abnormal neurological status
at admission; other major
injury leading to
hospitalization; hospital stay
>1 wk
n = 217 concussion; 221
minor injury controls
Attrition: 7.8%; 4%
Stats for concussion group:
Age:
M: 33 ± 13
F: 38 ± 14
Sex: 66% M
TSI: 7–14 d
IS: NR
AT: post-injury
BL/n = 217
t1: 3 mos/n = 200
t2: 1 yr/n = 192
Chi-square w/ Yates’
correction:
between-group
symptom comparison
2-Sided t test: VAS
score comparison
Multiple regression:
headache, cognitive
dysfunction VAS scores
as dependent,
demographic
characteristics as
independent
NR
Prior history of alcohol
abuse, drug abuse as
part of exclusion
criteria
Alcohol intolerance
31% at 3 mos
post-injury, 31% at 1 yr
post-injury
VAS fatigue item
Fatigue: score ≥50 on VAS
VAS fatigue scores:
BL: between-group differences
NS
t1 (p = .002):
Concussion: 50 ± 28
Control: 41 ± 29
t2 (p = .08):
Concussion: 50 ± 30
Control: 44 ± 28
VAS fatigue scores in
participants:
Married 1 yr (p = .17):
Concussion: 51 ± 30
Control: 45 ± 27
Unmarried 1 yr (p = .11):
Concussion: 49 ± 30
Control: 42 ± 29
With 1 yr high education
(p = .01):
Concussion: 52 ± 30
Control: 42 ± 27
With 1 yr low education
(p = .72):
Concussion: 47 ± 30
Control: 45 ± 29
NR
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Norrie et al. (2010)
NZ
Hospital
Prevalence, severity,
predictors, covariates of fatigue
in persons with mTBI
Longitudinal prospective
F/U: 3, 6 mos post-injury
IC: patients presenting to
hospital with mild closed head
injury; GCS 13–15;
LOC < 20 min; PTA < 24 h
EC: abnormal CT scan; regular
admission of psychoactive
drugs/history drug abuse;
central neurological
disorder/psychiatric condition;
skull/facial fractures/multiple
trauma/other major trauma
n = 159
Attrition: 14.1%; 10.6%
Age: 35.9 ± 15.6
Sex: 64% M
TSI: 1 wk;  ≤10 d
IS: GCS: mild
AT: post-injury
BL/n = 263
t1: 3 mos/n = 159
t2: 6 mos/n = 159
Pearson correlation
coefﬁcients: primary
dependent variables,
fatigue prevalence,
severity, energy,
depression, anxiety
associations
One-way ANOVA:
fatigue prevalence,
severity, energy change
Hierarchical
regression: t2 fatigue
severity with t1 fatigue
severity, depression,
anxiety
Receiver operating
characteristic curve:
sensitivity, speciﬁcity
of fatigue item on RPQ
in distinguishing those
w/  and w/o
pathological fatigue by
FSS at t2
NR
Regular intake of
psychoactive drugs,
history of drug abuse
as part of exclusion
criteria
FSS (severity)
RPQ fatigue item (prevalence)
SF-36v2 Vitality Subcale
FSS cut-off = 3.7
RPQ fatigue prevalence –
frequency of item rating ≥2
(max 4)
SF-36v2 Vitality high
score = low fatigue (max 100)
Frequencies:
BL:
FSS: 54.1%
RPQ: 67.3%
t1:
FSS: 35.8%
RPQ: 29.6%
t2:
FSS: 34%
RPQ: 26.4%
Scores:
BL:
FSS: 3.99 ± 1.53
RPQ: 2.09 ± 1.24
SF-36v2 Vitality: 46.57 ± 24.72
t1:
FSS: 3.3 ± 1.4
RPQ: 1.0 ± 1.1
SF-36v2 Vitality: 60.2 ± 19.7
t2:
FSS: 3.2 ± 1.4
RPQ: .96 ± 1.1
SF-36v2 Vitality: 62.1 ± 20.2
Correlations between
measures at time points
(p  ≤ .000, unless otherwise
indicated):
FSS BL w/: FSS t1: .53; FSS t2:
.49; RPQ BL: .57; RPQ t1: .30;
RPQ t2: .38; SF-36v2 BL: NS;
SF-36v2 t1: .42; SF-36v2 t2: .4
FSS t1 w/:  FSS t2: .76; RPQ BL:
.16 (p ≤ .05); RPQ t1: .45; RPQ
t2: .5; SF-36v2 BL: NS; SF-36v2
t1: .66; SF-36v2 t2: .39
FSS t2 w/:  RPQ BL: .2 (p ≤ .05);
RPQ t1: .4; RPQ t2: .62; SF-36v2
BL: NS; SF-36v2 t1: .56;
SF-36v2 t2: .59
Within-subject effects
BL-t2 (p < .0005):
FSS: F2,157 = 23.60;
2 = .23
RPQ: F2,157 = 60.556;
2 = .44
SF-36v2 Vitality:
F2,157 = 17.573; 2 = .18
Notes:
RPQ fatigue item –
unsatisfactory for
prediction of
pathological fatigue
post-mTBI
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Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
RPQ BL w/: RPQ t1: .24; RPQ t2:
.34; SF-36v2 BL: NS; SF-36v2
t1: −.2 (p ≤ .05); SF-36v2 t2:
−.2  (p ≤ .05)
RPQ t1 w/:  RPQ t2: .6; SF-36v2
BL: NS; SF-36v2 t1; −.57;
SF-36v2 t2: −.51
RPQ t2 w/:  SF-36v2 BL: NS;
SF-36v2 t1: −.52; SF-36v2 t2:
−.7
SF-36v2 BL w/: SF-36 t1/t2: NS
SF-36v2 t1 w/:  SFv2 t2: .69
Sensitivity/speciﬁcity of RPQ
fatigue item (i.e. discriminating
symptom at t2 on FSS):
BL, t1, t2: sensitivity = .74, .42,
.55; speciﬁcity = .63, .24, .12
Ponsford et al. (2012)
AU
Emergency and trauma
center
Report on post-concussive
symptoms and associated
cognitive, psychological,
functional outcomes in persons
with uncomplicated mTBI
Prospective
F/U: 1 wk, 3 mos  post-injury
IC: admitted to emergency and
trauma center;
trauma/acceleration-
deceleration movement to
head w/ LOC < 30 min,
PTA < 24 h, GCS 13–15 in last
24 h; ≥18 yrs; English-speaking
EC: general anesthesia after
injury; breath alcohol
>.05 mg/L at recruitment;
under inﬂuence of illicit drug
at injury; focal neurological
signs/seizures and/or
intracerebral abrnormalities
based on CT; dominant upper
limb injury disabling from use
of  computer mouse; spinal
precautions, cannot sit upright;
previous cognitive impairment,
neurological illness, major
alcohol/drug abuse, other
psychiatric impairment
affecting daily functioning; not
available for F/U
n = 123 (90 analyzed), 100
TC (TC) (80 analyzed)
Attrition: 9.8%; 18.9%
Stats for mTBI:
Age: 35.0 ± 13.1
Sex: 74% M
TSI: ≤24 hrs at BL
IS:  GCS: mild; PTA:
103 ± 191 min  (n = 118);
LOC: 61.4 ± 110 s (n = 111)
AT:
BL: ED/n = 123
t1: 1 wk/n = 90
t2: 3 mos/n = 90
qq, box plots;
Kolmogorov–Smirnov;
Shapiro–Wilk:
distribution normality
Univariate;
multivariate;
repeated-measures:
between-group score
comparison
Chi-square: categorical
variables, not normally
distributed
Mann–Whitney U:
continuous variables,
not normally
distributed
Wilcoxon Signed
Ranks; Friedman:
within-subject changes
over time
p = .05
Narcotic analgesics by
self-report:
BL: 62.6% mTBI, 44% TC
t1: 18.2% mTBI, 21.1%
TC
t2: 2.2% mTBI, 2.5% TC
PCS – post-concussive
symptoms checklist with
fatigue item
SF-36 Vitality (scores NR
separately)
Fatigue frequencies by PCS:
BL  (p < .001):
mTBI: 73.3%
TC: 47.5%
t1 (p = .019):
mTBI: 61.1%
TC: 42.5%
t2 (p = .424):
mTBI: 37.1%
TC: 22.5%
SF-36 Vitality:
TC signiﬁcantly higher median
pre-injury, t1 score (z = −3.11,
p  = .002; z = −2.96, p = .007)
t2: mTBI had lower mean score
vs.  TC (z = −2.33, p = .020)
NA
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Schoenberger et al.
(2001)
US
Tx seekers/patients of
neurolo-
gists/rehabilitation
clinics
Preliminary study of efﬁcacy of
FNS in persons with TBI
Preliminary experimental
randomized
F/U: post-tx: 3 mos
IC: mild-mod sev closed head
injury; informed consent
EC: penetrating head injury;
substance abuse/psychotic
diagnosis pre-injury; seizure
pre-/post-injury;
pregnant/trying to get
pregnant
n = 12; 2 groups: 1:
immediate tx; 2: waitlist
control
Attrition: 0
Age: 21–53
Sex: 16.7% M
TSI: 36 mos–21 yrs; mean:
7.7 yrs
IS: mild (75%); mod  sev
(25%); PTA (self-report):
41.7%; LOC: 1–27 d
AT:
t1: 1: pre-tx; 2: BL
t2: 1: post-tx; 2: pre-tx
t3: 1: 3 mos post-tx; 2:
post-tx
t4: 1: NA; 2: 3 mos  post-tx
ANCOVAs:
between-group
ANOVAs:
within-group; changes
over time
p = .05 (not adjusted for
multiple tests)
Change in medication
with tx: NA (33.3%);
eliminated (25%);
decreased (16.7%); no
change (25%)
MFI  – general fatigue, physical
fatigue, mental fatigue,
reduced motivation, reduced
activity
Fatigue by MFI: 5-point
severity scale/item; subscale
scores 4–20 – higher score,
greater severity
Stratiﬁed MFI  scores by group
and time point:
1: t1, t2: total (74.8 ± 20.4,
48.5 ± 20.9); general
(17.2 ± 4.0, 9.8 ± 4.8); physical
(16 ± 6.2, 10 ± 3.5); mental
(17.2 ± 3.3, 10.3 ± 6.3); reduced
activity (14.3 ± 5.6, 11.3 ± 5.4);
reduced motivation (10.2 ± 4.8,
7  ± 2.8)
2: t1, t2: total (61.5 ± 18.9,
61.3 ± 20.6); general
(14.8 ± 4.2, 14 ± 4.6); physical
(10.5 ± 4.5, 10.8 ± 5.3); mental
(15.5 ± 3.8, 15.7 ± 3.5); reduced
activity (10.7 ± 4.7, 10.8 ± 5.3);
reduced motivation (10 ± 3.9,
10 ± 4.9)
Stratiﬁed MFI  scores by
time-point:
Pre-tx: total (68.1 ± 20.8);
general (15.6 ± 4.4); physical
(13.4 ± 6.2); mental
(16.4 ± 3.3); reduced activity
(12.6 ± 5.4); reduced
motivation (10.1 ± 4.6)
Post-tx: total (50.1 ± 19.0);
general (11.2 ± 4.8); physical
(9.8 ± 3.3); mental (11 ± 4.9);
reduced activity (10.1 ± 4.8);
reduced motivation (8 ± 3.6)
F/U: total (47.3 ± 20.0); general
(10.5 ± 5.1); physical
(9.3 ± 5.0); mental (10.7 ± 4.4);
reduced activity (8 ± 4.2);
reduced motivation (7.7 ± 4.4)
Between-group
comparison of MFI
scores: total (F = 3.68,
p < .1); general (F = 8.04,
p < .05); physical
(F = 2.88); mental
(F = 9.10, p < .05);
reduced activity
(F = .24); reduced
motivation (F = 1.99)
Changes in MFI  scores:
total (F = 8.43, p < .01);
general (F = 6.5, p < .01);
physical (F = 4.02,
p < .05); mental
(F = 14.68, p < .001);
reduced activity
(F = 3.48, p < .1);
reduced motivation
(F = 2.72, p < .1)
Signiﬁcant differences
(p < .05):
Pre-post, F/U: total,
general, mental
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Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Sigurdardottir et al.
(2009)
NO
Level I trauma center
Study cognitive recovery 3–12
mos  post-TBI; use of
neuropsychological tests to
predict functional outcome
Prospective
F/U: post-injury: 3, 12 mos
IC: admission to trauma center
with acute TBI; 16–55 yrs;
≤24 h post-injury; ﬂuency in
Norwegian
EC: earlier neurological
disorder; spinal cord injuries
w/  current TBI; severe
psychiatric
disorders/substance abuse
n = 115; mild n = 40; mod
n  = 34; sev n = 41
Attrition: 7.8%
Age (at injury): mild:
35.9 ± 11.4; mod:
33.5 ± 10.8; sev:
28.5 ± 10.4
Sex:
mild: 63% M;  mod: 74% M;
sev: 71% M
TSI: ≤24 h (at recruitment)
IS:
Mild: GCS (14.7 ± .6); PTA
(.08 (range 0–1) d);
AIShead ≥ 3 (23%); ISS ≥ 15
(15%); intracranial
pathology by CT/MRI (28%)
Mod: GCS (10.8 ± 1.3); PTA
(5.25 (range 0–30) d);
AIShead ≥ 3 (79%); ISS ≥ 15
(68%); intracranial
pathology by CT/MRI (85%)
Sev: GCS (5.5 ± 1.8); PTA
(35.83 (range 0–128) d);
AIShead ≥ 3 (100%); ISS ≥ 15
(98%); intracranial
pathology by CT/MRI
(100%)
AT: post-injury
t1: 3 mos/n = 115
t2: 12 mos/n = 106
Parametric statistics
(Pearson) chi square:
categorical variables
ANOVA:
between-severity
group comparison
Multiple regression:
demographic, IS
predictors
Principal components
analysis w/ varimax
rotation:
neuropsychological
variable assessment at
t2 (to reduce predictors
in multiple regression)
Bonferroni corrections:
signiﬁcant tests w/
multiple comparisons
Post hoc: cognitive
functioning in mild TBI
p < .05 (2-tailed)
At t2, drug/alcohol use
by Alcohol use
disorders identiﬁcation
test
Alcohol >once/mo
(chi(8) = 24.1, p < .01):
mild, mod (48%); sev
(27%)
n  = 106
Alcohol and/or drugs
2–3×/wk: 13%;
≥4×/wk: 7%
FSS: avg 1–7 across 9 items –
total 0–7 (higher score, more
fatigue)
t2, between-severity groups:
NS; mean score: 4 ± 1.8
At t1,  fatigue (along w/ 2/3
cognitive components, PTA,
intracranial pathology) as a
predictor of Glasgow Outcome
Scale-Extended (GOSE) at t2:
signiﬁcant (R2 = .61, p < .001)
Fatigue, by FSS, as predictor of
GOSE at t2: B = −.13; SE = .04;
ˇ = −.25 (p < .001)
Signiﬁcant correlations at t2:
fatigue w/  (n = 96):
Memory/speed: −.38 (p < .001)
Verbal/reasoning: −.2 (p < .01)
GOSE: −.39 (p < .001)
NR
Notes:
Less fatigue predicts
better outcome
No effects of sex,
education, TBI severity
on fatigue at t2
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Sundstrom et al. (2007)
SE
Longitudinal
prospective cohort
study sample
Study self-reported fatigue
incidence pre- and post-mTBI;
compare incidences at time
points to controls; examine
association between fatigue
and APOE 4 genotype
Longitudinal population-based
F/U: post-injury
IC: in subset of previous
longitudinal study (previously
tested); participated in ≥2
evaluations in previous study
EC: missing data; mini-mental
state examination score <23;
not genotyped; dementia at
1st/2nd/3rd evaluation in
previous study
n = 31 mTBI; 62 controls
Attrition: 0
Stats for mTBI:
Age (at entry): 55.2 ± 13.6
Sex: 58.1% M
TSI (n = 18):
(injury-post-seccion):
19.7 ± 14.5 mos
IS (self-report, conﬁrmed
w/ criteria): mild
AT:
BL: pre-injury (previous
study)
F/U: post-injury
Controls: 1st, 2nd
assessments from previous
study
McNemar’s test:
differences pre- to
post-injury; for
controls, differences
1st to 2nd assessment
Fisher’s exact test:
between-group
comparison (i.e. mTBI
vs. controls)
NR Yes/no questions about
presence of fatigue
Fatigue presence: Yes to “Do
you often feel fatigued?”
Fatigue frequencies:
Pre-injury/1st assessment:
mTBI: 16.1%
Control: 25.8%
Post-injury/2nd assessment
(p < .05):
mTBI: 41.9%
Control: 19.4%
Post-injury fatigue in mTBI w/
APOE 4: 58%; w/o APOE 4:
32%
2nd assessment fatigue in
controls w/ APOE 4: 17%; w/o
APOE 4: 21%
mTBI w/  APOE 4 vs. control w/
APOE 4: signiﬁcant (p = .02)
mTBI w/o APOE 4 vs. control
w/o APOE 4: NS (.52)
Fatigue frequency
within-group change:
mTBI: signiﬁcant
(p < .05)
Control: NS
van der Naalt et al.
(1999)
NL
Hospital
Report long-term outcomes in
persons w/  mild-mod head
injury, GCS 9–14, irrespective
of length of hospital stay and
CT abnormalities; examination
of complaints, return to work;
whether GCS scores at
admission and length of PTA is
predictive of outcome
Prospective
F/U: post-injury: 1, 3, 6, 12 mos
IC: 15–65 yrs; GCS 9–14 at
hospital admission; PTA ≥ 1 h
EC: earlier admission for head
injury; history of drug/alcohol
abuse; psychiatric
disorder/mental retardation
diagnosis; severe aphasia
interfering w/ report of PTA;
PTA ≥ 28 d
n = 67
Attrition: 0
Age: 33.2 ± 14.7
Sex: 64.2% M
TSI: 1–2 h post-injury at
hospital admission
IS: GCS mean: 12.6 (range
9–14); PTA mean:
7.8 ± 7.3; range 1–30 d)
Mild: 64.2%
Mod: 35.8%
AT: post-injury:
t1: 1 mos
t2: 3 mos
t3: 6 mos
t4: 12 mos
Student’s
t/Mann–Whitney U
tests: where
appropriate
Pearson’s correlation
coefﬁcients:
independent measure
associations
  analysis:
interobserver scoring
Chi-square w/
correction for
continuity: frequencies
Multivariate regression
by stepwise backward
method
Outcome variables
distribution: normal
for scales w/ ≥4 points;
all else categorical
NR
History of addiction to
alcohol or drugs as part
of exclusion criteria
Alcohol intolerance at
1, 3, 6 mos and 1
year = 6, 11, 17 and
20%, respectively
Fatigue as complaint on
symptoms checklist
Fatigue frequencies at time
points:
t1: 57%
t2: 61%
t3: 45%
t4: 45%
At all time points, features as
1/6 most frequent complaints
No correlation between injury
characteristics and complaints
at all time points
NR
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Table 1 (Continued)
Reference
Country
Sample by
Objective
Design
Follow-up (F/U)
Inclusion/exclusion criteria
(IC/EC)
Sample size
Attrition
Age, sex (% M)
Time since injury (TSI)
Injury severity (IS)
Assessment time points/N
assessed (AT: t1, t2, etc.)
Statistical method Medications Results
Fatigue deﬁnition
Frequencies, scores
Score differences over
time
Notes
Yang et al. (2009)
TW
Level I trauma center
Study early clinical predictors,
PCS in mTBI persons with
persistent symptoms 2 mos
post-injury; study w/i a study
Prospective
F/U: post-injury: 1, 2, 8 wks
IC: mTBI patients from other
prospective study
EC: could not be reached for
F/U
n = 180; 2 mTBI groups: 1:
persistent PCS (PPCS)
n = 17; non-PPCS n = 163;
control group n = 40
Attrition: 0
Age:
1:  37.2 ± 14.2
2: 35.7 ± 16.4
Sex:
1: 41% M
2: 48% M
TSI: recruitment at ED
IS: GCS mean:
1: 14.9 ± .3
2: 14.9 ± .3
Intracranial lesions:
1: 53%
2: 15%
AT: post-injury:
t1: 1 wk
t2: 2 wks
t3: 8 wks
Chi-square:
associations of PCS
items in groups 1 and 2
Logistic regression:
predictors of mTBI w/
PPCS
p  < .05
NR Checklist of PCS (CPCS)
featuring fatigue item
Fatigue frequencies by CPCS:
mTBI:
t1: 23%
t2: 11%
t3: 3%
Fatigue frequency within 2
mos (previous study):
Control (n = 40): 8%
Fatigue frequencies by CPCS by
group:
1: t1: 24%; t2: 35%
2: t1: 23%; t2: 9%
t1: OR = .02
t2: OR = 2.76
Fatigue as one of most
common PCS in group 1
Fatigue strongly associated
with PPCS incidence at t2:
2 = 11.12, p < .01
NR
APOE 4 apolipoprotein-4; BDI, Beck depression inventory; BFS, Barroso fatigue scale; BL, baseline; CNS, central nervous system; CPCS, checklist for post-concussion syndrome; CT, computed tomography; d, day; ED, emergency
department; IC/EC, inclusion/exclusion criteria; IS, injury severity; ISS, injury severity score; FSS, fatigue severity scale; FNS, ﬂexyx neurotherapy system; F/U, follow-up; GCS, Glasgow coma scale; GOSE, Glasgow outcome
scale-extended; GFI, global fatigue inventory; LOC, loss of consciousness; MFIS, modiﬁed fatigue impact scale; MRI, magnetic resonance imaging; MHI, mild head injury; mTBI, mild traumatic brain injury; mos, months; NR, not
reported; NS, not signiﬁcant; PCS, post-concussion syndrome; PCSC, post-concussion syndrome checklist; POMS,  proﬁle of moods scale; PPCS, persistent post concussive syndrome; PTA, post traumatic amnesia; RPQ, Rivermead
post-concussive questionnaire; PSQI, Pittsburgh sleep quality index; SF-36, 36-item short form health survey (from medical outcomes study); TC, trauma controls; TBI, traumatic brain injury; tx, treatment; TSI, time since injury;
SSRI,  selective serotonin reuptake inhibitor; VAS, visual analog scale; wks, weeks; yrs, years.
T. Mollayeva et al. / Neuroscience and Biobe
Table  2
Summary of reported predictors of fatigue.
Study Measure and purpose in study 
De Leon et al. (2009) MOS  SF-36 Vitality subscale
• Severity measure (i.e. low score indicates
Norrie et al. (2010) FSS
• Frequency measure (i.e. score ≥3.7 indica
RPQ fatigue item
• Frequency measure (i.e. symptom rating 
fatigue)
MOS  SF-36v2 Vitality subscale
• Severity measure (i.e. low score indicates
Sundstrom et al. (2007) Fatigue question
• Frequency measure (i.e. answer “yes” to q
you often feel fatigued?” indicates fatigue)
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qPOE 4, apolipoprotein-4; MOS  SF-36v2 NS, not signiﬁcant – 36-item short form h
PQ,  Rivermead post-concussive questionnaire; wk, week.
i.e. untreated group) data and no effect data (i.e. intervention has
ot effect) were utilized to address the second research objective
i.e. to determine the course of fatigue) in patients with TBI.
Study quality was independently assessed by two  reviewers (TM
nd TK), using guidelines developed by Hayden et al. (2006) for
ssessment of prognostic studies (Table 4). The appraisal was  per-
ormed in two steps. First, the items related to six potential sources
f bias (i.e. study participation and attrition, associated factors and
utcome measurements, confounding measurement, and analyses)
ere assessed, then presence of potential biases was judged “Yes”,
Partly”, “No”, or “Unsure”. To summarize the level of evidence,
e used a system similar to the Scottish Intercollegiate Guidelines
etwork (SIGN) methodology (SIGNPG, 2013): (i) “+++” when all or
ost of the quality criteria proposed by Hayden et al. were fulﬁlled
i.e. allowing one “Partly” while appraising all potential sources of
ias); (ii) “++” when the majority of criteria were fulﬁlled; (iii) “+”
hen few criteria were fulﬁlled (i.e. at least one “Yes”). Addition-
lly, as proposed by SIGN, studies with retrospective data collection
id not receive a “++” rating, as this design is weaker than prospec-
ive data collection. We  refer to group (i) as ‘high quality studies’;
roup (ii) as ‘good quality studies’; and group (iii) as ‘fair quality
tudies’.
.6. Data synthesis
A best-evidence synthesis approach was applied, synthesizing
ndings from studies with sufﬁcient quality through tabulation and
ualitative description (Slavin, 1995; Carroll et al., 2004a).
Results were grouped into three main categories: prognostic
actors of fatigue, course of the fatigue, and consequences of fatigue
Tables 1–3). For studies utilizing measures of fatigue prevalence,
ample size-weighted mean frequencies were reported. Fatigue
everity measures used in the studies were reported with their cor-
esponding sample mean scores. To determine the course of fatigue,
atching assessment times (i.e. time post-injury that fatigue was
easured) were grouped, with their corresponding fatigue fre-
uencies, and a sample size-weighted mean frequency value was
alculated for time points with more than one contributing fre-
uency value (i.e. more than one study reporting fatigue at thathavioral Reviews 47 (2014) 684–716 703
Results: predictors of fatigue
 more fatigue)
Predictors of severity at 12 months
• Baseline fatigue (p = .000)
• Counseling for mental health (p = .016)
•  Medical disability (p = .012)
•  Marital status (p = .006)
•  Litigation involvement (p = .044)
NS
• Sex (p = .762)
• Age (p = .507)
Education (p = .77)
Prior drug/alcohol treatment (p = .382)
Motor vehicle crash (p = .444)
Injury type (p = .792, p = .427)
tes fatigue)
≥2 indicates
 more fatigue)
Predictor of severity at 3 mos
•  Severity at wk 1 (FSS) (R = 0.53; p < .000)
Predictor of severity at 6 mos
•  Severity at wk 1 (R = 0.49; p < .000)
•  Severity at 3 mos (R = 0.76; p < .000)
• Depression at 3 mos (B = .12; SE = .04;  ˇ = .25; p < .0000)
• Anxiety at 3 mos  (B = −.01; SE = .03;  ˇ = −.04; p = .610)
uestion “Do
Predictor of frequency post-injury
• APOE 4 genotype (p = .02)
 survey vitality subscale (from medical outcomes study); FSS, fatigue severity scale;
time point). Fatigue resolution/exacerbation/no change designa-
tions were reported.
Prognostic factors associated with fatigue were extracted for all
cohorts and untreated/no effect RCTs. All factors inﬂuencing the
course of fatigue, as reported by authors, were considered asso-
ciated with fatigue and not necessarily causal factors. To address
our third research objective (i.e. health consequences of fatigue in
TBI), we evaluated reports of poor health outcomes associated with
fatigue after TBI.
2.7. Zero-time
The nature of our research questions related to fatigue in the TBI
population (i.e. prognostic factors, course, and consequences) raises
the issue of zero-time bias. In prognostic studies, testing should
start at a deﬁned point, called zero time (Giobbie-Hurder et al.,
2013; van Rein et al., 2014). Designated zero times (i.e. baseline or
ﬁrst assessment) varied between studies included in this review.
For this reason and to best address our research questions, studies
were grouped based on whether baseline assessments were con-
ducted before or after the one-month post-injury mark. This point
was arbitrarily set.
2.8. Missing data
Primary authors were contacted in the case of missing data. In
the case of duplicate publications and companion papers of a pri-
mary study, we  attempted to maximize the yield of information by
the simultaneous evaluation of all available data (i.e. all data nec-
essary to address the three objectives of research, see Section 2.5).
Original publications took priority.
3. Results
3.1. Literature search and quality assessmentOf 2745 articles identiﬁed, 33 were selected for full-text review
(Lidvall et al., 1974; Ponsford et al., 2012; De Leon et al., 2009;
Lundin et al., 2006; Meares et al., 2011; Mickeviciene et al., 2004;
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Table  3
Summary of reported consequences of fatigue.
Study Measure and purpose in study Results: consequences of fatigue
Norrie et al. (2010) FSS
• Frequency measure (i.e. score ≥3.7 indicates fatigue)
RPCQ fatigue item
•  Frequency measure (i.e. symptom rating ≥2 indicates
fatigue)
RPSQ
•  Presence/problem status of 16 post-concussional
symptoms
Predictors of persistent PCS (RPSQ total) at 6 mos
•  Fatigue severity at wk 1(R = 0.40; p < .000)
•  Fatigue severity at 3 mos (R = 0.53; p < .000)
Sigurdardottir et al. (2009) FSS
• Severity measure (i.e. higher score indicates more
fatigue)
Full sample
Predictor of GOSE
• Fatigue severity at 3 mos (R2 = .61, p < .001)
Predictor of GOSE at 12 mos
•  Fatigue severity by FSS (B = −.13; SE = .04;  ˇ = −.25; p < .001)
mTBI
Predictor of GOSE at 12 mos
•  Fatigue severity by FSS (R2 = .47, p < .01)
Moderate/severe TBI
•  Fatigue severity by FSS (R2 = .58, p < .001)
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cSS, fatigue severity scale; GOSE, Glasgow Outcome Scale-Extended; mTBI, mild tr
ost-concussion symptom questionnaire; wk,  week.
orrie et al., 2010; van der Naalt et al., 1999; Yang et al., 2009;
cLean et al., 1993; Sundstrom et al., 2007; Hutchinson et al., 2009;
igurdardottir et al., 2009; Kempf et al., 2010; Driver and Ede, 2009;
emmell and Leathem, 2006; Bushnik et al., 2008a; Jha et al., 2008;
aiser et al., 2010; Khateb et al., 2005; Schoenberger et al., 2001;
ou et al., 2012; Bhambhani et al., 2008; Bateman et al., 2001;
ushnik et al., 2008b; Cooper et al., 2009; Hillier et al., 1997; Wiart
t al., 2012; Kim et al., 1999; Haboubi et al., 2001; Olver et al., 1996;
ees and Bellon, 2007) and 22 were included in the ﬁnal review
able 4
uality assessment of studies using guidelines developed by Hayden et al. (2006).
Study Study par-
ticipation
Time-zero Study
attrition
Prognost
factor
Bushnik et al. (2008a) No Yesi Yesd NA 
De Leon et al. (2009) No No Partlya No 
Driver and Ede (2009) Partlye Yesi No NA 
Gemmell and Leathem (2006) Partlye Yesi Not sure NA 
Hou et al. (2012) No Yesi No No 
Hutchinson et al. (2009) Partlye No Not sure NA 
Jha et al. (2008) No Yesi No Partlyg
Kaiser et al. (2010) Partlye Yesi No Not sure
Kempf et al. (2010) No Yesi No NA 
Khateb et al. (2005) Partlye Yesi Partlya NA 
Lidvall et al. (1974) No No No NA 
Lundin et al. (2006) No No No NA 
McLean et al. (1993) No No No NA 
Meares et al. (2011) No No Partlya No 
Mickeviciene et al. (2004) No No No NA 
Norrie et al. (2010) No No Partlya No 
Ponsford et al. (2012) No No Partlya NA 
Schoenberger et al. (2001) Partlye Yesi Not sure NA 
Sigurdardottir et al. (2009) No Yesi No No 
Sundstrom et al. (2007) No No No sure No 
van der Naalt et al. (1999) No No No NA 
Yang et al. (2009) No No Partlya No 
es – yes, sources of potential bias are presented; No – no potential bias; Not sure – n
ontacted); NA – not applicable according to the study design or type of analyses used.
a Not all required information about study attrition was  provided.
b A study does not address the possibility of confounding.
c Some errors in analyses performed were observed: e.g. limited details about analyses
d Completeness of follow-up was not adequate.
e Small sample size.
f Detail information about measure used was  not provided or used measure was not va
g Analyses performed were not adequate.
h Not all important covariates were included or exclusion criteria are not completed.
i Baseline assessment performed after 1 month post-injury.tic brain injury; mos, months; PCS, post-concussion syndrome; RPCSQ, Rivermead
(Fig. 2) (Lidvall et al., 1974; Ponsford et al., 2012; De Leon et al.,
2009; Lundin et al., 2006; Meares et al., 2011; Mickeviciene et al.,
2004; Norrie et al., 2010; van der Naalt et al., 1999; Yang et al., 2009;
McLean et al., 1993; Sundstrom et al., 2007; Hutchinson et al., 2009;
Sigurdardottir et al., 2009; Kempf et al., 2010; Driver and Ede, 2009;
Gemmell and Leathem, 2006; Bushnik et al., 2008a; Jha et al., 2008;
Kaiser et al., 2010; Khateb et al., 2005; Schoenberger et al., 2001;
Hou et al., 2012). Supplementary Table 2 reports reasons for exclu-
sion of 11 studies (Bhambhani et al., 2008; Bateman et al., 2001;
ic Outcome Confounding
measurement
and account
Analysis Reason for
exclusion
Overall
assessment
No No No – +
No No No – +++
No Not sure No – +
No No Partlyc – +
No Partlyh No – +
No Yesb No – +
No No No – +
 No No No – +
No No Partlyc – +
Partlyf Partlyh Partlyc – +
Partlyf Partlyh Partlyc – ++
Partlyf Partlyh No – ++
Partlyf No Partlyc – ++
No Partlyh No – ++
No No Partlyc – +++
No Partlyh No – ++
No Partlyh Partlyc – +
No No Partlyc – +
No Partly No – +
Partlyf No No – ++
Partlyf Partlyh No – ++
Partlyf Partlyh No – +
ot enough details were reported to make a decision (in some cases authors were
.
lidated.
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Articles identified through database 
search (N=2745): Emba se (n=1128), 
Medline (n=724), PsycINFO (n=453), 
CINAH L (n=265),  Coc hrane datab ase of 
systematic reviews (n=175) 
Other articles iden tified (i.e.  through 
scan of references of relevan t articles) 
(n=3)
Articles screened (n=2748)
Duplicates excluded (n=2388)
Excluded based on title (n=169)
Remaining articles (i.e. after exclusion based 
on title, removal of duplicates) (n=191)
Excluded based on abstract/full text 
(n=94)
Excluded based  on  format (i.e. 
conference presen tations, the ses, etc. ) 
(n=8)
Articles  assessed for eligibility (i.e. reading 
full tex t) (n=8 9)
Excluded based  on  inclusion criteria 
(N=56): not refereed (n=21), no measu re 
of fatigue (n= 16),  stud y design  (i.e. no t 
lon gitudinal) (n=9),  no separate  analysis 
of TBI patients (n= 5); foc us on differen t 
construct (i.e. apathy, sleepine ss, etc.) 
(n= 5)
Articles  to next round  (n= 33)
Excluded based  on quality assessmen t 
(n=6)
Inabilit y to  obtain information after 
contacting author(s) (n=3)
Same population in multiple studies (i.e. 
included oldest stud y) (n=2)
Articles  inc luded in review  (n=22)
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/18/2013); Cochrane (2005-3/2013).
ushnik et al., 2008b; Cooper et al., 2009; Hillier et al., 1997; Wiart
t al., 2012; Kim et al., 1999; Haboubi et al., 2001; Olver et al., 1996;
ees and Bellon, 2007; Meares et al., 2011). Main analyses featured
1 inception cohort studies with baseline assessment performed
ithin one-month post-injury (Lidvall et al., 1974; Ponsford et al.,
012; De Leon et al., 2009; Lundin et al., 2006; Meares et al., 2011;
ickeviciene et al., 2004; Norrie et al., 2010; van der Naalt et al.,
999; Yang et al., 2009; McLean et al., 1993; Hutchinson et al.,
009). Separate analyses of studies with baseline assessment after
ne month included 11 studies (McLean et al., 1993; Sundstrom
t al., 2007; Sigurdardottir et al., 2009; Kempf et al., 2010; Driver
nd Ede, 2009; Gemmell and Leathem, 2006; Bushnik et al., 2008a;
ha et al., 2008; Kaiser et al., 2010; Khateb et al., 2005; Schoenberger
t al., 2001; Hou et al., 2012), among them six RCTs (Driver and Ede,11/2013); Medline (1946-4/14/2013); PsycINFO (1806-4/7/2013); CINAHL (1980-
2009; Gemmell and Leathem, 2006; Jha et al., 2008; Kaiser et al.,
2010; Khateb et al., 2005; Schoenberger et al., 2001).
All 22 studies (Lidvall et al., 1974; Ponsford et al., 2012; De Leon
et al., 2009; Lundin et al., 2006; Meares et al., 2011; Mickeviciene
et al., 2004; Norrie et al., 2010; van der Naalt et al., 1999; Yang et al.,
2009; McLean et al., 1993; Sundstrom et al., 2007; Hutchinson et al.,
2009; Sigurdardottir et al., 2009; Kempf et al., 2010; Driver and Ede,
2009; Gemmell and Leathem, 2006; Bushnik et al., 2008a; Jha et al.,
2008; Kaiser et al., 2010; Khateb et al., 2005; Schoenberger et al.,
2001; Hou et al., 2012) were assessed as having “Partly” or “No”
on all bias criteria. Two studies (De Leon et al., 2009; Mickeviciene
et al., 2004) were of high quality (“+++”), six (Lidvall et al., 1974;
Lundin et al., 2006; Norrie et al., 2010; van der Naalt et al.,
1999; McLean et al., 1993; Sundstrom et al., 2007) were of good
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uality (“++”) and the remaining 14 (Ponsford et al., 2012; Yang
t al., 2009; Hutchinson et al., 2009; Sigurdardottir et al., 2009;
empf et al., 2010; Driver and Ede, 2009; Gemmell and Leathem,
006; Jha et al., 2008; Kaiser et al., 2010; Khateb et al., 2005;
choenberger et al., 2001; Bushnik et al., 2008b) were of fair quality
“+”). The latter group were penalized by the SIGN criteria (SIGNPG,
013) for incomplete statistical analysis, potential confounders,
election bias due to study attrition, and/or zero-time bias (Table 4).
.2. Study characteristics
Tables 2–4 summarize the study characteristics pertinent to our
esearch questions: population characteristics, deﬁnitions of TBI,
eﬁnitions of fatigue, follow-up time, statistical analysis methods,
nd study results. Means were calculated for the reviewed studies’
ample data.
.3. Studies with baseline assessment up to one month
ost-injury
Eleven studies featured a total of 1366 participants with TBI.
ine studies performed recruitment at emergency departments,
ospitals, or trauma centers, making up 91% of the total group
n = 1244) (Lidvall et al., 1974; Ponsford et al., 2012; De Leon et al.,
009; Lundin et al., 2006; Meares et al., 2011; Mickeviciene et al.,
004; Norrie et al., 2010; van der Naalt et al., 1999; Yang et al.,
009). One study recruited participants from the community (7.5%
f the sample, or n = 102) (McLean et al., 1993). One study featured
niversity athletes within four days of concussion, making up 1.5%
f the sample (n = 20) (Hutchinson et al., 2009).
Nine studies featured strictly participants with mild TBI (Lidvall
t al., 1974; Ponsford et al., 2012; De Leon et al., 2009; Lundin et al.,
006; Meares et al., 2011; Mickeviciene et al., 2004; Norrie et al.,
010; Yang et al., 2009), one examined mild to moderate TBI (van
er Naalt et al., 1999), and one included all TBI severities (McLean
t al., 1993).
The study samples comprised males in a range between 42%
De Leon et al., 2009) and 69% (Lidvall et al., 1974), with a mean
2.1 ± 9.5% across studies. One study did not report a sex ratio, stat-
ng the sample consisted mainly of single males, and was  included
n the mean calculation as 75% male (McLean et al., 1993). The mean
ge ranged between 20.1 (Hutchinson et al., 2009) and 41.2 years
f age (De Leon et al., 2009), with a mean 33.5 ± 5.6 years across
tudies. Mean time since injury (TSI) to baseline assessment ranged
rom one day (Lundin et al., 2006) to one month (Mickeviciene et al.,
004), and the mean TSI across all studies was 0.34 ± 0.38 months,
r 10.2 ± 11.4 days.
.4. Studies with baseline assessment after one month post-injury
Eleven studies (Sundstrom et al., 2007; Sigurdardottir et al.,
009; Kempf et al., 2010; Driver and Ede, 2009; Gemmell and
eathem, 2006; Bushnik et al., 2008a; Jha et al., 2008; Kaiser et al.,
010; Khateb et al., 2005; Schoenberger et al., 2001; Hou et al.,
012) featured a total 482 participants. Eight of these studies
ecruited from the community, making up 43.4% of the total group
i.e. n = 209) (Sundstrom et al., 2007; Sigurdardottir et al., 2009;
empf et al., 2010; Driver and Ede, 2009; Gemmell and Leathem,
006; Bushnik et al., 2008a; Kaiser et al., 2010; Schoenberger et al.,
001). Bushnik et al. (2008a) (n = 51) and Sigurdardottir et al. (2009)
n = 115) recruited from an inpatient rehabilitation center and a
evel 1 trauma center, respectively. Hou et al. (2012) recruited
rom the emergency department (n = 107), with baseline assess-
ent performed at a laboratory at a later time.
Seven studies featured participants with all severities of TBI
Sigurdardottir et al., 2009; Kempf et al., 2010; Driver and Ede,havioral Reviews 47 (2014) 684–716
2009; Gemmell and Leathem, 2006; Jha et al., 2008; Kaiser et al.,
2010; Schoenberger et al., 2001), two  comprised patients with
moderate to severe TBI (Bushnik et al., 2008a; Khateb et al., 2005),
and two  with mild TBI (Sundstrom et al., 2007; Hou et al., 2012).
The percentage of males ranged between 17%(Schoenberger
et al., 2001) and 85% (Kaiser et al., 2010), with a mean 62 ± 19.2%
across samples. The mean age ranged from 31 years (Bushnik et al.,
2008a) to 55.2 years of age (Sundstrom et al., 2007), with a mean
39.9 ± 6.6 years across studies. Mean TSI, across the ten studies, was
39.5 ± 35.5 months (i.e. 1185 ± 1065 days) and baseline assessment
times ranged from 2.6 months (Bushnik et al., 2008a) to 8.6 years
post-injury (Gemmell and Leathem, 2006).
3.5. Assessment of TBI
Considerable between-study variation was  observed in TBI
diagnostic criteria and deﬁnitions, irrespective of TSI at baseline
assessment (Tables 1–3). Most studies (17/22) used a combinatorial
approach to conﬁrm and assess TBI, using tools such as the Glas-
gow Coma Scale (GCS), duration of posttraumatic amnesia (PTA)
and loss of consciousness (LOC), and clinical evaluation (Lidvall
et al., 1974; Ponsford et al., 2012; De Leon et al., 2009; Lundin et al.,
2006; Meares et al., 2011; Mickeviciene et al., 2004; Norrie et al.,
2010; van der Naalt et al., 1999; Yang et al., 2009; McLean et al.,
1993; Hutchinson et al., 2009; Sigurdardottir et al., 2009; Gemmell
and Leathem, 2006; Bushnik et al., 2008a; Jha et al., 2008; Khateb
et al., 2005; Hou et al., 2012). Three studies (Sundstrom et al., 2007;
Driver and Ede, 2009; Schoenberger et al., 2001) used other meth-
ods, including patient report, description of damage and/or lesions
based on medical records, and diagnoses of referring professionals.
Two studies used GCS scores alone (Kempf et al., 2010; Kaiser et al.,
2010).
3.6. Methods used for assessing fatigue
Measures used to assess fatigue in the TBI population varied
depending on the study objectives. Studies where fatigue was not
a main focus most commonly used a single item for the symp-
tom within a checklist with broad symptom coverage (9/22) (e.g.
Rivermead post-concussion questionnaire (RPQ) and the post-
concussion syndrome checklist (PCSC)) (Tables 2 and 3). If fatigue
was studied more extensively, standardized measures looking at
different aspects of the symptom, such as momentary perception,
chronic characteristics, impact of fatigue on function, rating/rank of
fatigue intensity/severity and dimensions of fatigue (i.e. cognitive,
physical) were utilized. Four of the 22 studies used more than one
measure to assess fatigue. All fatigue scales were designed for other
populations, with some having psychometric properties described
in the TBI population (Supplementary ﬁle 3).
3.6.1. Multi-item scales
Most studies (14/22) assessed fatigue based on standardized
self-report measures – four used the fatigue severity scale (FSS)
(Sigurdardottir et al., 2009; Kempf et al., 2010; Jha et al., 2008;
Kaiser et al., 2010); four – the short-form health survey-36 (SF-
36) vitality subscale (Ponsford et al., 2012; De Leon et al., 2009;
Norrie et al., 2010; Gemmell and Leathem, 2006); two – a visual
analog scale (VAS) for fatigue (Mickeviciene et al., 2004; Gemmell
and Leathem, 2006), and two  – the proﬁle of mood states (POMS)
fatigue-inertia scale (Hutchinson et al., 2009; Driver and Ede, 2009).
One study assessed fatigue with the Barroso fatigue scale (BFS), a
synthesis of ﬁve independent scales, with additions (Bushnik et al.,
2008a). The BFS yields FSS and global fatigue index (GFI) scores. One
study utilized the modiﬁed fatigue impact scale (MFIS) (Jha et al.,
2008), one used the fatigue assessment inventory (Khateb et al.,
2005), and one again used the multidimensional fatigue inventory
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Schoenberger et al., 2001). We  refer the reader to Supplementary
le 3 for descriptions of measures.
On the FSS, participants rate their level of agreement with
espect to nine statements about the severity of fatigue and its
mpact on everyday activities (Krupp et al., 1989). The total score is
he mean, and higher scores indicate greater fatigue. In some cases,
tudies reported frequency of fatigue by the FSS, deﬁning presence
f the symptom as a total score ≥4 (Kempf et al., 2010; Kaiser et al.,
010), or ≥3.7 (Norrie et al., 2010). Others used FSS scores as indi-
ators of fatigue severity (Sigurdardottir et al., 2009; Bushnik et al.,
008a; Jha et al., 2008).
On the four-item SF-36 vitality subscale, participants choose,
n a six-point scale, the frequency of events related to fatigue
nd energy (Ware, 1992). Fatigue item means are combined with
everse-scored energy means to yield a total score. Two studies
tilized two different versions of the measure (i.e. SF-36 and SF-36
ersion 2). SF-36 and the updated SF-36 version 2 are comparable
n terms of scores.
.6.2. Single item assessment of fatigue
Nine papers used a single item or question to assess fatigue
Lidvall et al., 1974; Ponsford et al., 2012; Lundin et al., 2006;
eares et al., 2011; van der Naalt et al., 1999; Yang et al., 2009;
cLean et al., 1993; Sundstrom et al., 2007; Hou et al., 2012), pre-
enting TBI patients with a list of symptoms (e.g. Rivermead PCSQ,
CS checklist, etc.), including fatigue. One study determined pres-
nce of fatigue by participants’ ‘Yes’ responses to the question, “Do
ou often feel fatigued?” (Sundstrom et al., 2007).
.6.3. Multiple measures of fatigue
Four studies used more than one measure to assess fatigue
Ponsford et al., 2012; Norrie et al., 2010; Gemmell and Leathem,
006; Jha et al., 2008). Gemmell and Leathem (2006) utilized the
F-36 vitality subscale with the VAS for fatigue, for a measure of
atigue severity. Jha et al. (2008) worked with the FSS and MFIS
nd reported change in severity of fatigue with use of medications.
orrie et al. (2010) utilized the SF-36 vitality subscale with the RPQ
or severity and frequency values. The SF-36 vitality subscale was
sed again by Ponsford et al. (2012) together with a single item
rom the PCS checklist, to report frequency and severity of fatigue
cross time.
.7. Overall predictors of fatigue
Only studies with baseline assessment prior to one month post-
njury investigated predictors of fatigue. All statistically signiﬁcant
redictors of fatigue identiﬁed are reported in Table 2. Three stud-
es, one of high quality and two of moderate quality (De Leon et al.,
009; Norrie et al., 2010; Sundstrom et al., 2007) identiﬁed eight
actors signiﬁcantly associated with fatigue in TBI patients (Table 3).
he factors comprised earlier fatigue severity, signiﬁcant in two
tudies (De Leon et al., 2009; Norrie et al., 2010), carriage of the
polipoprotein E 4 allele, signiﬁcant in one study (Sundstrom et al.,
007), having seen a counselor for a mental health issue, medical
isability, marital status (i.e. widowed, divorced, or separated) and
itigation involvement, all signiﬁcant in one study (De Leon et al.,
009), and depression, also signiﬁcant in one study (Norrie et al.,
010). One moderate quality study did not ﬁnd a signiﬁcant effect
f sex, education, or TBI type/severity on fatigue in a fully adjusted
odel (Norrie et al., 2010). In that same study, anxiety at three
onths was not a predictor of fatigue at six months (Norrie et al.,
010).havioral Reviews 47 (2014) 684–716 707
3.8. The course of fatigue
Mean frequencies of fatigue at time points with more than one
reported value (i.e. two or more studies reported frequency at the
same time post-injury) were weighted based on sample size. For
studies where baseline assessment was conducted prior to or at
one month post-injury, mean weighted frequencies were 46.6%
(SD = 32.7, n = 206) (Lidvall et al., 1974; Ponsford et al., 2012), 45.9%
(SD = 24.8, n = 637) (Lidvall et al., 1974; Ponsford et al., 2012; Norrie
et al., 2010; Yang et al., 2009), 17.3% (SD = 13.6, n = 325) (Lidvall
et al., 1974; Meares et al., 2011; Yang et al., 2009), 45.2% (SD = 29,
n = 230) (Lidvall et al., 1974; van der Naalt et al., 1999; McLean
et al., 1993), 30.5% (SD = 11.7, n = 830) (Lidvall et al., 1974; Lundin
et al., 2006; Mickeviciene et al., 2004; Norrie et al., 2010), 32.4%
(SD = 7.3, n = 269) (Norrie et al., 2010; van der Naalt et al., 1999) and
37.4% (SD = 8.1, n = 354) (Mickeviciene et al., 2004; van der Naalt
et al., 1999; McLean et al., 1993) for two  days, six days-one week,
two weeks, one month, three months, six months and one year
post-injury, respectively. The number of studies contributing to the
mean for a particular time point ranged from two  studies for two
days and six months post-injury to seven studies for three months
post-injury (Fig. 3a).
For studies with baseline assessment after one-month post-
injury, just one mean weighted frequency value was obtained for
one time point, 22.8% (SD = 5.4, n = 172) (Kempf et al., 2010; Hou
et al., 2012) at six months post-injury. Two studies contributed
values for calculation of this mean. The remaining time points com-
prised single studies and therefore one frequency value (Fig. 3b).
3.9. The course of fatigue, by injury severity
When fatigue frequency calculations were stratiﬁed by injury
severity, mean weighted frequencies could only be obtained for
the mild TBI group with baseline assessments conducted less than
or at one month after injury. The frequencies of fatigue were 46.6%
(SD = 32.7, n = 206) (Lidvall et al., 1974; Ponsford et al., 2012), 45.9%
(SD = 24.8, n = 637) (Lidvall et al., 1974; Ponsford et al., 2012; Norrie
et al., 2010; Yang et al., 2009), 17.3% (SD = 13.6, n = 325) (Lidvall
et al., 1974; Meares et al., 2011; Yang et al., 2009) and 27.8%
(SD = 7.8, n = 763) (Lidvall et al., 1974; Ponsford et al., 2012; Lundin
et al., 2006; Meares et al., 2011; Mickeviciene et al., 2004) for two
days, six days-one week, two weeks and three months post-injury,
respectively. The number of studies contributing to the means
ranged from two  studies for two days post-injury to six studies
for three months. The mild TBI group with baseline assessments
performed after one-month post-injury and mild to moderate and
mixed groups all had one contributing study each. The studies fea-
turing moderate to severe TBI did not report fatigue frequencies.
For the purpose of comparison of fatigue frequencies between
mild TBI and other severities, studies reporting frequencies in sam-
ples of mild to moderate and mixed severities of TBI were grouped.
Mean frequencies were 66.3% (SD = 8.5, n = 147) (van der Naalt et al.,
1999; McLean et al., 1993) and 46.2% (SD = 1, n = 162) (van der Naalt
et al., 1999; McLean et al., 1993) for one month and one-year post
TBI, respectively. The two  contributing studies had baseline assess-
ment performed within the ﬁrst month post-injury.
3.10. Fatigue severity
In two studies using the FSS, the sample mean scores at 12
months were 3.20 ± 1.39 (Norrie et al., 2010) and 2.9 ± 1.6 (Bushnik
et al., 2008a). One study, using an alternate FSS scoring system
(Jha et al., 2008), reported similar fatigue severity. In the two  stud-
ies that utilized the SF-36 vitality subscale and the SF-36 vitality
subscale version 2, the mean scores at one year post-injury were
62.11 ± 20.18 (Norrie et al., 2010) and 49.6 ± 11.83 and 52.3 ± 12.22
708
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Table 5
Fatigue measures and their corresponding scores at assessment.
Study Injury type/severity Assessment Measure Sev(BL) Sev(t1) Sev(t2) Sev(t3)
Bushnik et al. (2008b) TBI/mod-sev t1: 2.6 ± 1.8 mos
t2: 12.6 ± 1.2 mos
t3: 23.2 ± 3.4 mos
GFI NR 23 ± 10 17 ± 11 20 ± 11
FSS  3.4 ± 1.5 2.9 ± 1.6 3.2 ± 1.8
De Leon et al. (2009) 1: HI w/ PTA and/or LOC/mild
2: HI only/mild
BL: ED
t1: 1 mo
t2: 3 mos
t3: 12 mos
SF-36v 1: 52.8 ± 9.53
2: 50.4 ± 10.48
NR NR 1: 52.3 ± 12.22
2: 49.6 ± 11.83
Driver and Ede (2009) TBI control/NR BL: before start
t1: 8 wks  later
POMS
fatigue-inertia
subscale
1.24 ± .61 1.29 ± .57 NA NA
Gemmell and Leathem
(2006)
TBI control/NR BL: before start
t1: 6 wks  later
SF-36v 47.50 ± 20.18 38.75 ± 4.43 NA NA
Hutchinson et al. (2009) TBI/mild BL: ≤96 h post-injury
t1, t2, t3: 3 non-consecutive d over 2
wks
POMS
fatigue-inertia
subscale
≈4.3 ≈8 ≈6.8 ≈4.4
Jha et al. (2008) 1: TBI/mild-sev modaﬁnil ﬁrst
2:  TBI/mild-sev placebo ﬁrst
BL: before start
t1: 4 wks
t2: 10 wks
MFIS 1:
46.56 ± 19.28
2:
47.17 ± 15.53
1:
38.65 ± 16.09
2:
36.45 ± 15.03
1: 35.63 ± 20
2:
33.55 ± 18.16
NA
FSS 1:
45.22 ± 11.82
2:
44.46 ± 12.17
1:
39.36 ± 15.61
2:  37.7 ± 12.55
1:
37.13 ± 18.33
2:
36.91 ± 14.08
NA
Khateb et al. (2005) Brain injury/PTA 8 ± 10 d BL: before start
t1: 3 mos
29-item fatigue
scale
132.6 ± 27.3 126.1 ± 32.3 NA NA
Mickeviciene et al. (2004) Concussion/NR BL: ED
t1: 3 mos
t2: 1 y
VAS fatigue
item
NR 50 ± 28 50 ± 30 NA
Norrie et al. (2010) TBI/mild t1: 1 mo
t2: 3 mos
t3: 12 mos
SF-36 Vitality NR 46.57 ± 24.72 60.21 ± 19.68 62.11 ± 20.18
FSS  NR 3.99 ± 1.53 3.29 ± 1.44 3.20 ± 1.39
Ponsford et al. (2012) TBI/mild BL: ED post-injury
t1: 1 wk
t2: 3 mos
PCSC Checklist NR ≈2.8 ≈2.2 NA
Schoenberger et al. (2001) Closed HI/mod-sev BL: before start
t1: 6–8 wks  later
MFI: Gen 14.83 ± 4.17 14.00 ± 4.56 NA NA
MFI: Phys 10.50 ± 4.51 10.83 ± 5.34
MFI: Men  15.50 ± 3.83 15.67 ± 3.50
Sigurdardottir et al. (2009) TBI/mild-sev BL: ED
t1: 3 mos
t2: 12 mos
FSS NR NR 4.0 ± 1.8 NA
BL, baseline; ED, emergency department; FSS, fatigue severity scale; GFI, global fatigue inventory; LOC, loss of consciousness; MFIS, modiﬁed fatigue impact scale; MFI, multidimensional fatigue inventory; HI, head injury; TBI,
traumatic brain injury; mos, months; NR, not reported; NA, not applicable; PCSC, post-concussion syndrome checklist; POMS, proﬁle of moods scale; PTA, post-traumatic amnesia; sev, severity; SF-36 V, 36-item short form health
survey  vitality subscale (from medical outcomes study); TBI, traumatic brain injury; VAS, visual analogue scale; wks, weeks; y, year.
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ig. 3. (a) Reported frequencies of fatigue for studies with time zero ≤1-month post-i
or two TBI subgroups (De Leon et al., 2009). Other researchers who
tilized the same standardized scales could not be compared on
he basis of their measurement of fatigue at different time points,
r missing data on scores (Table 5).
.11. Impact of fatigue after TBI
One study where baseline assessment took place prior to one
onth post-injury and one with baseline assessment at three
onths post-injury investigated consequences of fatigue.
Table 4 shows lists the consequences signiﬁcantly associated
ith fatigue. One study of moderate quality looked at the rela-
ionship of fatigue with persistent post-concussive symptoms
Norrie et al., 2010), and one of fair quality looked at its associa-
ion with the Glasgow outcome scale-extended (GOSE) total score
Sigurdardottir et al., 2009).
Persistent post-concussive symptoms:  Fatigue severity at one
eek and three months predicted persistent post-concussive
ymptoms at three months and six months, respectively, con-
rolling for litigation, psychological/neurological disorders, and
ubstance abuse (Table 4) (Norrie et al., 2010).
GOSE total score: An association with the GOSE score was
ound in Sigurdardottir et al.’s study controlling for education, PTA,
ntracranial pathology and relevant psychological tests in multi-
ariate regression analysis models. In the mild TBI group, the FSS
otal score was a signiﬁcant predictor of GOSE score (R2 = 0.47;
 < .001), explaining 23% of the total variance in GOSE score at one
ear post-injury. Similar results were obtained for the moderate to
evere TBI group (R2 = 0.58; p < .001) (Table 4).
.12. Associations of fatigue with other clinically important
ariables
.12.1. Studies with baseline assessment up to one month
ost-injury
Lundin et al. (2006) found poor memory, sleep disturbance
nd fatigue to be most commonly reported within their sample,
ith early symptom overlap correlated with later results. Similarly,
eares et al. (2011) found symptom overlap of fatigue, insomnia,
nd irritability at ﬁve days and three months post-injury, with some690d 1080d
. (b) Reported frequencies of fatigue for studies with time zero >1-month post-injury.
participants recovering from and others developing the symptoms
as time went on.
Norrie et al. found a signiﬁcant increase in the percentage of
those with fatigue reporting depression and/or anxiety, both symp-
toms over the cut off indicating mild severity, at six months after
injury, compared with reports at three months. This increase coin-
cides with a leveling off of fatigue percentages. As fatigue becomes
persistent, psychological factors such as anxiety and depression
tend to worsen (Norrie et al., 2010).
Ponsford et al.’s mTBI group reported signiﬁcantly poorer gen-
eral health, vitality, and mental health, as demonstrated by their
scores in the corresponding subscales of the SF-36, compared to
trauma controls; however, a similar pattern was observed when
participants completed the same scales but with regard to their
pre-injury status. The authors highlighted the importance of docu-
menting pre-injury status in TBI studies.
3.12.2. Studies with baseline assessment after one month
post-injury
Bushnik et al., investigating changes in fatigue from 6 to 12
months post-injury, reported a signiﬁcant change in the Pittsburgh
sleep quality index (PSQI) scores: where fatigue increased, PSQI
scores were higher compared to cases where there was no change
or decreased fatigue. There were no other signiﬁcant group dif-
ferences on the pain VAS, disability rating scale, neurobehavioral
functioning inventory motor subscale, the Craig handicap assess-
ment and reporting technique (CHART) cognitive independence,
and CHART occupation (Bushnik et al., 2008a). The authors sug-
gested that, for TBI individuals who complain of fatigue, assessing
sleep quality would be a high-yield correlate and possibly treatable
with behavioral and/or medication interventions.
Kempf et al. reported no associations between fatigue parame-
ters and TBI severity, alcohol intake at time of injury, nor with sleep
duration, education, age or gender. They did, however, ﬁnd a mod-
erate correlation between FSS and depression symptoms assessed
with the Beck depression inventory (BDI) (r = 0.46, p = 0.001), and
with anxiety symptoms assessed with the Hospital anxiety and
depression scale (HADS) (r = 0.37, p = 0.007). They also reported
coincidence of fatigue and excessive daytime sleepiness (Kempf
et al., 2010).
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.13. Medications, drugs and alcohol
Seven of the 22 studies listed regular intake of psychoactive
rugs and/or history of drug or substance abuse prior to TBI in
tudy exclusion criteria (Mickeviciene et al., 2004; Norrie et al.,
010; McLean et al., 1993; Jha et al., 2008; Kaiser et al., 2010; Khateb
t al., 2005; Schoenberger et al., 2001). One study excluded persons
aking medications that cause sleep/wake disturbances, however,
etails were not provided (Kaiser et al., 2010). Eight of the 22 studies
id not report on use of medications/illicit drugs/alcohol by partici-
ants prior to or over the course of the study (Lidvall et al., 1974; De
eon et al., 2009; Lundin et al., 2006; Yang et al., 2009; Sundstrom
t al., 2007; Hutchinson et al., 2009; Gemmell and Leathem, 2006;
ou et al., 2012). Nine studies reported a variation of data. Bushnik
t al. (2008a) reported use of alcohol by 62% prior to the ﬁrst
ssessment, with 19% identiﬁed as drug users and heavy and/or
inge drinkers. Sigurdardottir et al. (2009) described, at the second
ssessment, use of alcohol more than once per month in 48% of mild
o moderate injured persons and in 27% of the severely injured. Use
f alcohol and/or drugs more than two or three times per week was
eported by 17%, and more than four times per week by 7% of partic-
pants (Sigurdardottir et al., 2009). Ponsford et al. (2012) included
reath alcohol levels at recruitment exceeding 0.05 mg/L of alcohol,
nﬂuence of illicit drugs at injury, history of signiﬁcant drug/alcohol
buse affecting daily functioning in their exclusion criteria. Those
eporting alcohol or cannabis use, and who did not have cognitive
ifﬁculties pre-injury were not excluded. The study reported fre-
uency of lifetime substance abuse to be 31.3% in the mTBI sample
nd frequency of substance abuse in the previous three months to
e 6.7% (Ponsford et al., 2012). Meares et al. (2011) reported use of
pioids/opiates by 59.7% across the ﬁrst and second assessments,
nd use of marijuana was reported in 24.4% of mTBI cases. In Driver
nd Ede’s study, 61.1% reported intake of selective serotonin reup-
ake inhibitors (SSRIs). One study indicated changes in medication
egimes of participants with ﬂexyx neurotherapy system treat-
ent, but did not clarify the nature of the changes (Schoenberger
t al., 2001).
. Discussion
.1. Factors associated with fatigue
When we sought evidence of a temporal relationship between
linically important factors and fatigue we focused on: (1) TBI pop-
lation characteristics (e.g. time since injury, severity of injury,
omorbid conditions, etc.) and (2) our outcome of interest (i.e.
atigue) – its frequency, severity, and deﬁnition, with the goal of
btaining a set of risk factors that can be used for prognosis. Table 4
resents a descriptive summary of the available evidence. In sum-
ary, several potential risk factors for fatigue in TBI have been
nvestigated, including those related to demographics and socio-
conomic status, injury severity, medical comorbidities, baseline
atigue levels, genetic makeup, and physical and cognitive inde-
endence.
Fatigue at baseline, occurring at any time from injury through
he acute care course, was found to be a primary predictor of symp-
om chronicity in TBI of varying severities (Norrie et al., 2010).
aseline fatigue was found to be one of the most powerful predic-
ors of fatigue at follow-up (De Leon et al., 2009; Norrie et al., 2010).
ther studies on chronic fatigue syndrome show similar associa-
ions between long-lasting fatigue and fatigue at baseline (Cairns
nd Hotopf, 1997; Nisenbaum et al., 2003; Kato et al., 2006), con-
urrent with the results of another study, where pre-stroke fatigue
as reported to be related to fatigue in the acute phase after stroke
Lerdal et al., 2011). Despite reports of an impact of baseline fatiguehavioral Reviews 47 (2014) 684–716
on outcome at follow-up, the clinically important “critical values”
of fatigue severity and duration following brain injury are not estab-
lished. Future research should record frequent and speciﬁc data in
investigation of the etiology of pre-morbid and baseline fatigue, and
control for multiple factor interactions, in addition to the magni-
tude of effect attributable to individual factors in analyses. More
attention needs to be paid to patients with intensive fatigue at
baseline, as it is related to prognosis.
Female sex, education, GCS score, and alcohol use at the time
of injury were reported to have no associative value for fatigue
severity in a study of mild TBI (Kempf et al., 2010). Differences in
severity and frequency of fatigue between men  and women  have
been observed after stroke (Lerdal et al., 2011), depression (Khan
et al., 2002), obstructive sleep apnea (Chervin, 2002), heart dis-
ease (Ekman and Ehrenberg, 2002), and cancer (Miaskowsky, 2004),
with females more often reporting fatigue than their male counter-
parts. Sex-related differences in fatigue were investigated in just
one reviewed study, and further research is warranted. Other fac-
tors associated with fatigue frequency and severity at follow-up,
reported reviewed studies, included carriage of the APOE 4 allele
(Sundstrom et al., 2007), counseling for mental health, medical
disability, speciﬁc marital status (i.e. widowed, divorced, or sepa-
rated), and involvement in litigation (De Leon et al., 2009). The APOE
4 allele in persons with TBI was  previously reported to be linked to
an increased risk of Alzheimer’s disease (Jellinger et al., 2001). In a
study of the general population (O’Hara et al., 2005), a relationship
between sleep apnea (SA) and dementia through the APOE 4 allele
was observed. Sleep apnea, highly prevalent in the TBI population
(Mollayeva et al., 2013b), may  explain the link between the APOE
4 allele and fatigue and dementia. While studies to date have out-
lined the separate relationships between TBI, SA, fatigue, the APOE
4 allele, and dementia, their complex interaction requires rigorous
study.
4.2. Frequency, severity and course of fatigue in TBI
This systematic review underlines the variation in frequency of
fatigue that exists after TBI, regardless of studies’ set time zeros
(Fig. 3a and b). Changes in the proportion of participants reporting
fatigue from the start of the study to its completion also varied,
some reporting gradual or abrupt increases or decreases, and oth-
ers reporting frequency ﬂuctuation over the course of study. A
steep drop in frequency was observed at two  weeks post-injury,
with most of the contributing studies featuring mTBI patients. This
drop might be explained by the current clinical management of
mTBI, including the prescription of a rest period of at least two
weeks after injury. As fatigue is inﬂuenced by the degree of physi-
cal and/or cognitive exertion, as well as the amount of rest one has
received, it is possible that a mildly injured person, after completing
a course of rest, would not perceive fatigue; however, their fatigue
could resume when they return to regular duties and responsibili-
ties. Unchanged frequencies were commonly associated with RCTs
with close follow-up times (e.g. 1–3 months). The observed varia-
tion in the natural history of fatigue post TBI may  be related to the
tools utilized by the different researchers, and the constructs those
tools measured. Respondents’ interpretations of the construct of
fatigue, as well as its complex underlying pathogenesis with differ-
ent mechanisms inter-related at different time points, are expected
to inﬂuence the results obtained.
The dimensions assessed in the studies utilizing fatigue scales or
single items included momentary perception, chronic perception,
the impact of fatigue on function, rating of tiredness, dimensions
of fatigue (i.e. mental, physical), or severity of the fatigue (Supple-
mentary ﬁle 3). The various measures also attach different weights
to different aspects of fatigue, depending on the conceptualization
of fatigue by the developer (Chaudhuri and Behan, 2004). In some
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tudies, fatigue was conceptualized as a one-dimensional entity in
hich persons are deemed either fatigued or not fatigued based
olely on their perception of the experience at the time of comple-
ion.
Interpretation of scale items by the respondent can be sig-
iﬁcantly confounded by the association of fatigue with other
ymptoms, particularly apathy, excessive sleepiness, depression,
ack of motivation, anxiety, litigation and cognitive dysfunction. In
BI patients, fatigue was reported to be associated with depression;
oreover, in the regression analyses in one reviewed study (Norrie
t al., 2010), the severity of fatigue was predicted by depression.
empf et al. (2010) reported that fatigue and excessive daytime
leepiness coincided in their sample. Excessive daytime sleepiness
ay  be an indicator of central nervous system (CNS) pathology
ue to brain injury (i.e. hypocretin/orexin deﬁciency), as well as
elated to quantity and quality of sleep (Mollayeva et al., 2013b;
aumann, 2012; Nardone et al., 2011; Mathias and Alvaro, 2012;
iebern and Guilleminault, 2012). While Kempf et al. (2010) stud-
ed and did not uncover a relationship between fatigue and sleep
uration, quality of sleep was not investigated. A number of sleep
isorders (i.e. sleep-related breathing disorder, periodic leg move-
ent disorder, etc.) highly prevalent post-TBI (Nardone et al., 2011;
ollayeva et al., 2013c) are characterized by frequent arousals,
hich generally result in fragmented sleep, which can produce day-
ime sleepiness (Stepanski, 2002). Bushnik et al. (2008a) suggests
ssessment of sleep quality as a valuable measure when studying
BI patients with fatigue complaints.
Symptoms of fatigue and cognitive dysfunction have been
eported to overlap in persons with TBI (Johansson et al., 2009;
aben et al., 2013). This can potentially inﬂuence accuracy of self-
eport, as a person with cognitive dysfunction may  not be able
o fully grasp the changes in fatigue since their injury, as well
s its impact on daily functioning, as required in completion of
ertain self-report measures. Bushnik et al. (2008a) reported that
 subset of individuals who experienced signiﬁcant increase in
atigue over the ﬁrst two years post-injury demonstrated poorer
utcomes in cognition, motor symptoms, and general functioning
ompared to those with decreased or stable fatigue (Bushnik et al.,
008a). A separate study had similar ﬁndings – subjective men-
al fatigue following brain injury was correlated with objectively
easured information processing speed (Johansson et al., 2009). In
ther literature again, post-traumatic conditions such as hypopitu-
tarism have been reported to have a wide range of manifestations,
ncluding fatigue, myopathy, cognitive difﬁculties, depression, and
ehavioral changes (Zaben et al., 2013). The same degree of fatigue,
herefore, will not be perceived with equal intensity by persons
ith different comorbid conditions or fatigue etiology. Moreover,
atigue manifestation is thought to be differentially modulated by
 variety of factors within and between TBI persons with time.
istinguishing fatigue as a result of TBI from fatigue associated
ith comorbid conditions (i.e. depression, pain, anxiety, apathy,
leep dysfunction, medication effect, etc.) is a complicated task. As
uch, future research should consider use of additional measures
or common comorbidities when assessing PTF.
Fatigue severity (i.e. mean FSS scores) was higher in persons
ith TBI than previously reported for healthy adults (2.3 ± 0.7)
Krupp et al., 1989), but lower than those in patients with systemic
upus erythematosus (SLE) (4.7 ± 1.5) (LaChapelle and Finlayson,
998), rheumatoid arthritis (4.2 ± 1.2) (Krupp et al., 1989) and pso-
iatic arthritis (6.9 ± 2.4) (Cella et al., 2005). Bushnik et al. (2008a)
eported FSS scores obtained at 6, 12, and 18–24 months post-
njury, all falling within the score range for non-fatigued control
ubjects (Table 5).
Studies differed in reports of fatigue severity over time, with
ome noting changes with and others stability. It is plausible
hat time since injury is a determinant of effectiveness of copinghavioral Reviews 47 (2014) 684–716 711
strategies and thereby perception of symptom severity. A study
of persons with chronic fatigue syndrome (Brown et al., 2010)
reported better adaptive coping strategies with longer disease
duration. Alternatively, spinal cord injury patients showed no
changes in coping styles over time (Craig et al., 1994). Future lon-
gitudinal studies of coping by persons who sustained a TBI may
provide greater insight. Age differences between samples should
also be considered. In a study of fatigue in the general population,
Cella et al. (2002) reported that people older than 50 years in the
described more severe fatigue than the younger population. The
mean age in samples of reviewed studies reporting fatigue sever-
ity ranged from 20.1 ± 1.8 (Hutchinson et al., 2009) to 45.7 ± 10.8
(Gemmell and Leathem, 2006). We  did not observe relationship
between age and severity of reported fatigue, however (Table 5).
Other factors related to the discussion of fatigue severity have to
do with the impact of brain injury on a person’s ability to perform
pre-morbid duties and manage responsibilities. Diminished activ-
ity due to changes in lifestyle, with subsequent loss of muscle tone
and weakness, or muscle weakness due to neurological impair-
ment, can result in greater fatigue perception associated with mild
activity (Chaudhuri and Behan, 2004).
4.3. Consequences of fatigue in TBI
Possible consequences of fatigue emerged in the studies
reviewed. Fatigue severity one week post-injury was associated
with persistent post-concussive symptoms at three months (Norrie
et al., 2010), and the FSS total score was  signiﬁcantly associated
with the GOSE score for all severities of TBI (Sigurdardottir et al.,
2009). Post-concussion syndrome (PCS) itself refers to a group of
symptoms, including headache, dizziness, fatigue, and affective
and cognitive changes, that may  be reported by patients after TBI
(McAllister, 1994). Thus, it is possible that severe post-concussive
symptoms that are not resolved over a short period (i.e. three
months), inﬂuence fatigue outcomes. The fact that the GOSE, the
“gold standard” for assessing patient outcomes after TBI (Shukka
and Devi, 2011), was  affected by baseline fatigue severity across all
injury severities at one year post-injury is signiﬁcant, as it suggests
that fatigue can be long lasting, with a low likelihood of resolution.
Consequently, diagnostic efforts that consider diverse factors and
comorbid conditions (Figs. 1 and 2) should be implemented in the
very early stages post-injury.
4.4. Medication effects
CNS depressants can cause or increase fatigue (Liska, 2008). In
the reviewed studies, just seven included their use in the exclu-
sion criteria. Nine studies provided some information on the use
of medications/illicit drugs/alcohol by participants prior to or over
the course of the study. None, however, considered the potential
confounders in this relationship. Reported use of alcohol by 62%
of participants in the period before the ﬁrst assessment, with 19%
identiﬁed as drug users, heavy and/or binge drinkers is striking
(Sigurdardottir et al., 2009). Ethyl alcohol is a CNS depressant, and
the injured brain is particularly sensitive to its effects at the highest
centers (i.e. speech, thought, cognition) and lower brain functions
(i.e. spinal cord reﬂexes, respiration), as the dosage increases (Liska,
2008). Norrie et al. (2010) reported that alcohol intake prior to the
injury was not correlated with fatigue severity at three months
after injury, as measured by FSS, however, the researchers did not
report alcohol intake of participants throughout the course of the
study. This is signiﬁcant, as studies in the general population have
reported fatigue to be the most severe hangover symptom (Penning
et al., 2012; Rohsenow et al., 2007).
Intake of SSRIs was  reported by 61.1% of the participants in
Driver and Ede’s study. While this class of medications is a ﬁrst
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ine of treatment for depression following TBI (World Health
rganization, 2002), some drugs within this class (i.e. ﬂuoxe-
ine and paroxetine) may  be problematic due to their adverse
ffects, including those related to fatigue and cognitive function
Schmitt et al., 2001). Another reviewed study reported use of opi-
ids/opiates by 59.7% of participants (Meares et al., 2011). Opium
lkaloids are narcotic analgesics and narcosis is deﬁned by depres-
ion of the CNS leading to analgesia, drowsiness, changes in mood,
ental clouding, lethargy, apathy and subsequent unconsciousness
Shukka and Devi, 2011). While currently there is no strong evi-
ence directly relating physical and mental fatigue in TBI to side
ffects of opiates and opiods (Chapman, 2002; Leong and Royal,
004), data on its safety for chronic use is also lacking (Rhodes,
012). While our discussion of medication effects and fatigue in
BI is limited, given the complexity of the fatigue symptom and
ncomplete data available, future research should consider such
ffects, as the potential of medications to cross the blood–brain bar-
ier and mimic  neurological deﬁcits and cause or exacerbate PTF, is
eal (Daneman, 2012; Maher et al., 2011).
To complete our discussion, we follow with recommendations
or future research in the ﬁeld of fatigue and TBI. As mentioned,
long with the confounding effects and selection bias, the method
y which fatigue was measured contributed signiﬁcantly to the
ariation observed in results. The words that one uses to deﬁne
atigue can be vague, especially if the reporter (i.e. patient with TBI)
as additional complaints related to constructs such as excessive
leepiness and impaired alertness. As such, separate assessment
f each construct is preferable. When featured as one item within
 self-report measure, even when spontaneously endorsed and
anked as the most important symptom, patients may  rank their
atigue experience understanding it as being exhausted, tired,
eak, while others may  feel physically exhausted but mentally
lert. As such, a single question hampers interpretation of the score.
hile it is not always the case that multi-item instruments are
ore valid than a single item, especially if the global opinion of
he patient is of interest, adding one global item about the con-
truct to a multi-item symptom measure in the future can help in
he interpretation and validation of the instrument in the popu-
ation of interest. This is particularly relevant to the study fatigue
n the TBI population as, despite the number of multi-item stan-
ardized measures that have been utilized, only the FSS, the MFIS
nd the SF-36 have been partially validated against other fatigue
easures in a TBI sample. Moreover, there are no psychometric
ata on the responsiveness of these measures, implying limited
nderstanding of how much error exists when measuring changes
n fatigue over time. Currently, the ﬁeld of TBI requires further test-
ng of existing self-report measures whose psychometric properties
ere described in other target populations, focusing on measures
ertaining to the multidimensional etiology and state of PTF.
None of the studies reviewed applied technologies (i.e.
lectroencephalography, functional magnetic resonance imaging,
agnetic resonance spectroscopy, regional brain volumes, motor
voked potential, etc.) or markers of physiological processes
i.e. function of hypothalamic–pituitary–adrenal axis, autonomic
ervous system response, metabolic processes, immune system
esponse, etc.) to study the fatigue experienced by individuals with
BI. The latter is important, as research has shown that the resting
ulmonary and cardiorespiratory function in patients with TBI is
ompromised (Jankowski and Sullivan, 1990). This can be related
o deconditioning as a result of a more sedentary lifestyle (Giordon
t al., 1998). In a study of maximal physiologic responses dur-
ng exercise in patients with moderate to severe TBI at 17.2 ± 17
onths after injury, several weeks of an exercise training pro-
ram reduced physiologic fatigue (Bhambhani et al., 2005). Others
eported that aerobic ﬁtness in individuals with TBI enhanced cog-
ition and improved mood (Carroll et al., 2004b; Cassidy et al.,havioral Reviews 47 (2014) 684–716
2014). This is extremely important as fatigue perception ratings
were found to be higher in patients with depression (Norrie et al.,
2010). Again another study (Jankowski and Sullivan, 1990) reported
that a 16-week circuit training program of moderate intensity and
prolonged duration increased TBI patients’ oxidative capacity and
muscular endurance and the index of physiologic fatigability was
shown to be useful for the assessment and evaluation of individ-
uals with TBI. Similarly, in a reviewed study by Driver and Ede
(2009) fatigue elimination was  reported after an eight-week group
aquatic program, with no changes in fatigue in the control group.
Thus, further study that accounts for the physiologic, objective per-
formance, and/or homeostatic changes with regard to increased
perception/manifestation of fatigue after brain injury is within the
top priorities for future research.
4.5. Limitations
We  acknowledge heterogeneity in the primary studies with
respect to sample characteristics (i.e. age, injury/localization of
injury, time since injury) and fatigue deﬁnitions. Another concern
related to the reviewed studies, largely of “moderate” quality, is
that severe TBI is underrepresented in the inception cohorts and the
evidence for the second and third research questions of this review
was based largely on mild TBI cohorts. Additionally, the majority of
the patients in the studies were men, which limits the precision of
estimates of predictors and consequences for fatigue in severe TBI,
especially for women  (Table 2).
Most studies focused largely on the fatigue symptom; the
strength and signiﬁcance of associations with other factors (e.g.
sleep, other medical conditions, medication use or clinically impor-
tant symptoms such as alertness, sleepiness) were often not
reported. Thus, the roles of other factors could be underestimated
in this review.
The focus of this review was the natural history of fatigue in
patients with TBI. To be consistent with our protocol (Mollayeva
et al., 2013a), results from all selected longitudinal studies were
used to address the ﬁrst research question (i.e. natural history of
fatigue). Since baseline fatigue assessment was performed at dif-
ferent times since injury, we  attempted to mitigate zero-time effect
by reporting results with baseline assessments up to one month
post-injury and after one month, separately. Nevertheless, gener-
alizability of results remains unclear due to inadequate reporting of
selection criteria, poor control of confounding effects, and attrition.
There are limitations to the presented data on fatigue measures
used in the reviewed studies (Supplementary ﬁle 3). For con-
ciseness, properties of the measures, speciﬁcally those related to
psychometrics, were not reported in great detail. Despite attempts
to include all relevant articles for their use in the TBI population, it
is possible studies were missed.
All articles included in this review are peer-reviewed. As such,
there is possibility for publication bias. Finally, the inclusion of only
English language articles could affect the generalizability of our
ﬁndings.
4.6. Pitfalls and controversies
Despite the existence of clinical criteria for the diagnosis of PCS,
the self-reported nature of nonspeciﬁc symptoms such as fatigue
can be confounded by other factors (i.e. psychological distress, pain,
depression, etc.). This may  be particularly apparent in patients with
insurance claims that are being disputed. Their need to provide
proof of disability may  magnify fatigue symptoms and result in con-
troversy about whether symptoms are indicators of brain injury
or are of behavioral origin (Carroll et al., 2004b; Cassidy et al.,
2014). Also, fatigue as a symptom is nonspeciﬁc to TBI. Fatigue
appears with other diagnostic labels in other clinical specialities
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 for example ﬁbromyalgia, chronic fatigue syndrome, endocrine
isorders, and patients with psychiatric illness (Norrie et al., 2010;
airns and Hotopf, 1997; Nisenbaum et al., 2003; Kato et al., 2006;
erdal et al., 2011; Cassidy et al., 2014). Previous systematic reviews
n the epidemiology, diagnosis, prognosis, treatment and costs of
TBI raised the issue of speciﬁcity of self-reported symptoms such
s headache, fatigue, cognitive deﬁcits to mild TBI (Carroll et al.,
004b; Cassidy et al., 2014), with the recommendation to replace
he term post-concussion syndrome with the term post-traumatic
ymptoms.
The reviewed studies allowed comparison of fatigue severity
nly between mild TBI participants and controls, limiting our dis-
ussion to a single severity of injury. While concussed athletes
ad more fatigue compared to healthy controls at one week post-
njury, that was not the case at two weeks (Hutchinson et al.,
009). Similarly, fatigue was greater in the mild TBI group com-
ared to controls shortly after the injury, but not at three monthsin patients with traumatic brain injury.
post-injury in Lundin et al.’s and Meares et al.’s samples. De Leon
et al. (2009) found that fatigue severity at the one year follow-up
was not associated with the type of injury (i.e. mild TBI vs. non-head
injury) in a fully adjusted model. Pair-wise comparisons showed
lower fatigue scores in the mild TBI group at 12 months compared
to the other injury group. Contrariwise, Sundstrom et al. (2007)
reported that their mild TBI group had less fatigue pre-injury and
more post-injury compared to age-, sex-, and education-matched
controls.
Given this lack of speciﬁcity of the fatigue symptom, this topic
is perplexing and time consuming. An accurate investigation of
fatigue in TBI must begin with a clear deﬁnition of the most com-
mon  symptomatic descriptor, “feeling fatigued”. Next, the cause of
fatigue must be determined and a diagnosis established. Although
the pathophysiology of fatigue after TBI is still poorly under-
stood, the goal is to determine whether the fatigue is caused
by a correctable factor (i.e. depression, endocrine dysfunction,
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econditioning, poor sleep, etc.) so that interventions are applied
ppropriately. Fig. 4 illustrates the proposed algorithm for study of
TF.
. Conclusions
Fatigue is a common symptom post TBI. Its frequency may
hange over time, but fatigue can persist years after the injury.
his may  be related to pre-morbid/early fatigue, mental health
ssues, other medical conditions, and ongoing societal stressors.
linicians seeing patients with TBI at the acute stages post-injury
ith high early fatigue intensity, mental health issues, and litiga-
ion involvement should be aware that these may  be associated
ith the development of persistent post-concussive symptoms.
he available evidence on the associative value of these factors, as
ell as the consequences of fatigue, is currently not very strong,
s we found just three cohort studies addressing these issues.
ore research is needed to establish associations between fatigue
nd other clinically important pre- and post-morbid variables (i.e.
leep dysfunction, depression, physical and cognitive impairments,
ther medical/neurological disorders), and their impact on out-
omes post-injury. Medication effects, personal factors such as
oping ability, physical deconditioning, stress level, and time fac-
ors should also be investigated. This is particularly important for
ranslation of research into clinical practice, in order to address
isk factors and course of condition. An international consensus,
imilar to the National Institutes of Health and developed for reha-
ilitation in TBI in 1999 (Consensus Conference, 1999) advising on
ow best to study clinically important symptoms such as fatigue in
BI, is of utmost importance. In particular, there needs to be a con-
ensus on the deﬁnition of pathological PTF, set times for baseline
ssessment, recognizing the challenges in studying the symptom
n moderate-severe brain injury at time zero, clinically relevant
eriod of follow-up, acceptable attrition rates to ensure represen-
ative samples, and validated measures of outcome, all of which can
educe heterogeneity of results. What will be left to focus on then
s the variety of lesions from TBI (i.e. white or gray matter, spe-
iﬁc tract damage, lesion volume, localization of injury, etc.) and
nter-individual variability in perception and multifactorial fatigue
tiology, which may  ﬁnd study of individual patients best. A caveat
o this point is that case-reports of patients whose symptoms and
linical course do not ﬁt the typical picture, may  lead to scientiﬁc
rogress in the understanding of and appreciation for the complex-
ty of the fatigue symptom post TBI (Yennurajalingam and Bruera,
007).
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